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 Abstract 
Oligonucleotide cross-linking agents are expected to become a new class of 
antisense drugs. They function by first hybridizing with a complementary mRNA 
and then form a covalent bond to permanently link the mRNA to the oligonucleotide 
agent. Because of covalent cross-linking, this new class of antisense drugs are 
expected to have much higher potency than existing ones. 
Some oligonucleotide cross-linking agents have appeared in the literature, but they 
have various drawbacks, which include slow cross-linking rate and reversible 
cross-linking. To address these problems, we designed a series of new cross-
linking oligonucleotides with a range of different reactivities. These 
oligonucleotides were expected to react with complementary mRNA with higher 
rates and selectivity. To synthesize this new class of cross-linking agents, we used 
the Dmoc oligonucleotide synthesis technology recently developed in our 
laboratory. Using this new technology, oligonucleotide deprotection and cleavage 
were achieved under mild conditions, under which the cross-linking functions in 
our agents were kept intact. In contrast, if known oligonucleotide synthesis 
technologies had been used, the cross-linking functions would not have survived.  
After successful synthesis of the new class of cross-linking oligonucleotides, they 
were subjected to hybridization with complementary oligonucleotides under 
various conditions.  The progress of the hybridizations was monitored and 
analyzed with RP-HPLC and MALDI-TOF. At the current stage of the project, the 
xxiii 
properties of the cross-linking oligonucleotides were found to be less than ideal. 
However, successful synthesis of potential cross-liking oligonucleotides, 
development of key procedures and protocols for cross-linking experiments and 
development of analytical techniques to detect cross-linked products have paved 
the foundation for us to design and screen a series of similar oligonucleotides. 
Because as long as we can place the cross-linking function at proximity to a 
reactive site of complementary oligonucleotide, the two oligonucleotides will be 
forced to react, we believe that screening a series of oligonucleotides will provide 
desired cross-linking agents. 
 1   
1 Introduction 
1.1 Oligonucleotides 
Oligonucleotides are short nucleic acids. There is no strict rule found about the 
length of oligonucleotides. The term oligonucleotide has been used for a chain of 
nucleotides as small as 2 nucleotides to couple hundred nucleotides long. The 
general structures of DNA and RNA strands are shown in Figure 1.1; DNA 11 
composed of four nucleobases (adenine, cytosine, guanine and thymine), the 
phosphate backbone and a sugar moiety. RNA 12 on the other hand is slightly 
different with an extra hydroxyl group at 2' carbon on a sugar moiety and uracil 
replaces thymine.  
Oligodeoxynucleotides (ODNs) or DNAs are important members of oligonucleotide 
family. Two types of nucleobases; purines (adenine and guanine) and pyrimidines 
(cytosine and thymine) are present in a certain order to make DNAs functional. 
DNAs are primary genetic materials present mainly in the nucleus of the cell. DNAs 
can interact efficiently with complementary DNAs as well as complementary RNAs 
to form a double helix.[1] They also play significant role in cellular metabolism by 
producing mRNAs through transcription which is followed by the synthesis of a 
protein. Proteins control metabolic processes of the cell through various enzymes. 
Formation of protein is very vital for all physiological processes occurring in the 
body of an organism. 
RNAs on the other hand are like a carrier which carry different codes from genes 
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to other parts of the cell mainly to produce proteins and regulate cellular 
metabolism. They can be found both inside the nucleus and in the cytoplasm.   
 
Figure 1.1 Structure of oligonucleotides 
1.1.1 A brief history 
The oligonucleotide synthesis was first reported in 1955. Michelson and Todd 
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successfully synthesized a dinucleotide, dithymidinyl 13 (Figure 1.2).[2] The 
molecule 13 they synthesized was protected by benzoyl protection from both 5' 
and 3' ends.  
 
Figure 1.2 Dithymidinyl 
Har Gobind Khorana and co-workers reported the synthesis of series of 
oligonucleotides in late 1960s and throughout 1970s using phosphodiester 
coupling approach.[3-5] They reported the synthesis of an active 72 mer tRNA in 
1971.[3] During the same period Letsinger introduced solid support; first for the 
peptide synthesis and then for an oligonucleotide synthesis.[6] He also improved 
Khorana’s phosphodiester approach by introducing phosphotriester method.[7] 
Beaucage and Caruthers introduced phosphoramidite chemistry by replacing 
chlorine by an amine as a leaving group from phosphotriester.[8] This simple 
change later became a reason for the construction of first automated 
oligonucleotide synthesizer, ABI in 1980s. Manual oligonucleotide synthesis needs 
special synthetic skills and is cumbersome. With the advancements in automated 
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oligonucleotide synthesis, manual synthesis became virtually extinct. 
1.1.2 The current scenario 
Today, we can synthesize oligonucleotides from few nucleotides long to few 
hundred nucleotides long. An automation of the synthesis process and solid phase 
synthesis by phosphoramidite approach have made it possible to synthesize 
millions of different oligonucleotides simultaneously from milligram to kilogram 
scales.[9-15] The ability to chemically assemble oligonucleotides on a solid support 
efficiently has made a broad impact in last few decades on many research areas 
including molecular biology,[16, 17] chemical biology,[17-19] synthetic biology,[20, 21] 
data storage,[22, 23] nanotechnology[24, 25] and medicine.[17, 19, 26] The current 
research in the field is visibly focused on the applications of oligonucleotides.  
1.2 The need of modified oligonucleotides  
Natural DNAs have been used successfully for gene synthesis,[27] understanding 
structure and functions of biomolecules,[28, 29] transgenic crop development[30, 31] 
and many more. But they need to be modified for some of the important purposes. 
To mention few; areas of epigenetics,[32, 33] chemical ligation,[34, 35] oligonucleotide 
conjugates,[36-38] DNA damage repair,[39-41] mutagenesis,[42, 43] peptide fusion[44] 
and antisense drug development[32, 45] need modified oligonucleotides. Out of 
several useful functions of modified oligonucleotides DNA-protein interactions, 
sensitive nucleic acids and cross-linking agents are of special interest to us. It is 
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because they involve binding of biomolecules together which is the basis 
requirement for the development of an oligonucleotide cross-linking agent. These 
interactions are discussed in following paragraphs. 
1.2.1 DNA-protein interactions  
 
Figure 1.3 DNA-protein interactions 
It is well known that several proteins interact with DNAs.[28, 46, 47] Out of many such 
interactions, three different interactions A, B and C are shown in a Figure 1.3.[48, 
49] The interaction A shows the binding of a lambda repressor helix-turn-helix factor 
to its DNA target. Lambda repressor is a gene regulatory protein that binds to target 
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DNA by hydrogen bond formation and regulates a gene synthesis.[48, 50] The 
interaction B depicts the association of histones with DNA. This interaction checks 
the supply of transcription factor and makes gene expression slow.[29, 49] While third 
interaction C shows how restriction enzyme EcoRV binds to DNA. This binding  
eventually destroys the DNA.[51]  
The DNA-protein interaction mainly manages the length of a genetic material by 
controlling gene expression.[52] Because binding of protein to DNA regulates the 
structure of chromatin (a genetic part of DNA), transcription and DNA repair 
processes.[29, 53, 54] These interactions are very important in gene therapies to 
understand and treat genetic disorders like cancers. The intervention of such 
interactions is possible by modified DNAs to regulate the expression of a disease-
causing gene.[55-57] 
1.2.2 Sensitive nucleic acids 
Natural nucleic acids were considered only to have nucleobases adenine, guanine, 
cytosine and thymine in DNAs and adenine, guanine, cytosine and uracil in RNAs 
in their standard forms (Figure 1.1). Recent discoveries show that these 
nucleobases undergo different modifications which result into several sensitive 
nucleic acids containing modified nucleobases like N4-acetylcytosine 14, 5-
methoxycarbonylmethyl-2-thiouridine 15 and wybutosine 16 (Figure 1.4).[58] The 
sensitive nucleic acids possess a second layer of information that is mostly 
noncoding in nature. These nucleic acids bind to the target proteins and RNAs and 
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play significant roles in cellular metabolism.[58] So far over 100 such modifications 
are reported for RNAs but they are present in the trace amounts. There is a need 
for the synthesis of sensitive nucleic acid with such modifications to target cellular 
metabolic process that causes health problems.  
 
Figure 1.4 Sensitive nucleic acid bases 
1.2.3 Cross-linking agents 
Cross-linking oligonucleotide agents are usually synthetic and are recent entries 
to the field of nucleic acids. The modifications are designed to achieve cross-
linking between two oligonucleotide strands.[59] Cross-linking can occur between 
DNA-DNA, DNA-RNA and RNA-RNA strands. Cross-linking agents are used 
successfully along with dyes for the detection of cancers and several other genetic 
disorders.[60] The cross-linking by modified oligonucleotides has an ability to alter 
or stop the replication,[61] transcription[62, 63] and translation[63, 64] processes by the 
formation of cross-linked product with DNA or RNA. Oligonucleotides as cross-
linking agents have been widely studied by researchers for the development of 
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antisense drugs.[32, 65, 66] Antisense drugs can treat several genetic disorders 
selectively by stopping the synthesis of a disease-causing protein.  
The binding affinity of biomolecules (DNAs, RNAs and proteins) is the useful tool 
for bringing two molecules together and holding them together through a 
permanent linkage. Several oligodeoxynucleotide (ODN) cross-linking agents are 
already reported with some serious limitations. The limitations of current ODN 
cross-linking agents provide an opportunity for the development of an ‘ideal’ ODN 
cross-linking agent for antisense drug development.  
1.3 ODN cross-linking agent for an antisense drug development 
1.3.1 Known cross-linking agents and their limitations 
Several attempts have been made by synthetic chemists for the synthesis of an 
oligodeoxynucleotide cross-linking agent to facilitate antisense drug development. 
But almost all of them have a limited success.[67-70]  
In one such attempt (Scheme 1.1) oligodeoxynucleotide 17 containing 3-
cyanovinyl-carbazolenucleoside (CVCbN)  found to be cross-linked with the 
complementary DNA strand 18 on irradiation of UV light at 366 nm to produce a 
cross-linked product 19.[71] The change is temporary as cross-linking can be 
reversed by small increase in the energy to 312 nm to give back 17 and 18. The 
use of UV light itself can cause the non-selective irreversible damage to the cell as 
well as can produce unwanted gene mutations. 
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Scheme 1.1 CVCbN oligonucleotide cross-linking agent 
Another interesting cross-linking oligodeoxynucleotide agent was reported by 
Sasaki and co-workers in 2005 (Scheme 1.2).[59] They developed oligonucleotide 
20 containing 6-vinylpurines as a cross-linking agent and got relatively stable 
cross-linked product 21 under acidic conditions. The slower action and selectivity 
are two major limiting factors to use vinylpurines for the development of an 
antisense drug agents. To overcome these limitations several derivatizations were 
carried out over vinylpurines with slightly better cross-linking properties.[70, 72, 73] 
Though some improvements have been made over the period, they are not 
suitable for the development of an antisense drug. 
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Scheme 1.2 Vinylpurine oligonucleotide cross-linking agent 
1.3.2 An ideal oligodeoxynucleotide cross-linking agent 
Antisense drug binds to the mRNA and stops its supply for protein synthesis. 
Because no more mRNA is available no protein synthesis is possible. Different 
mRNAs carry different information or codes specific to a protein. So different 
proteins are synthesized by different codes and need their own mRNAs. The 
synthesis of a protein responsible for diseases like cancer can be selectively 
stopped by cross-linking of a responsible mRNA to the modified oligonucleotide 
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cross-linking agent. To make this possible cross-linking agent should possess 
following properties. 
1.3.2.1 Irreversible binding to mRNA 
Covalent cross-linking perhaps is the only way to form a permanent bond between 
two interacting entities; a modified oligodeoxynucleotide and mRNA strand. But 
even covalent bonds are reversible in nature.[71] Modifications should be made to 
achieve irreversible covalent bond. This specificity and some other difficulties 
discussed later in the following paragraphs make structural modifications of 
nucleobases difficult and leaves synthetic chemist with very few choices. 
Therefore, attempts are being made in the direction of putting electrophilic group 
on the modified nucleobase so that nucleophilic nitrogen on the natural 
nucleobases can react with it to form an irreversible covalent bond.[59, 71] Examples 
of oligonucleotide cross-linking agents discussed are designed by considering this 
point of view. Results are not very exciting but electrophile-nucleophile chemistry 
provides the best platform for the design of oligonucleotide cross-linking agents by 
offering plenty of choices. So, we decided to stick to the electrophile-nucleophile 
chemistry for designing a cross-linking agent that can form a permanent bonding 
between modified oligodeoxynucleotide and mRNA. 
1.3.2.2 Fast binding to targeted mRNA 
Oligodeoxynucleotide cross-linking agents reported so far are slower in actions or 
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they are somewhat faster but have reversible nature.[59, 70, 74] Antisense drug needs 
to be quicker in action and slow reactivity of cross-linking agent is bound to affect 
the pace of the drug action.  
1.3.2.3 High selectivity  
Sequence selectivity is very important to target a mRNA fragment specific to a 
disease-causing mRNA strand. This problem is mostly addressed by designing a 
longer non-coding oligodeoxynucleotide strand complementary to the target 
mRNA fragment.  
1.4 Our design of cross-linking agents for antisense applications 
Keeping ideal assumptions about the oligonucleotide cross-linking agent in mind 
modified nucleobases 1-5 (Figure 1.5) have been designed. The design is based 
on nucleophile-electrophile chemistry which works better when an electrophile has 
a leaving group. Previous attempts failed to provide a suitable leaving group for a 
nucleophilic attack to produce a permanent covalent bond.[59, 70-73] Absence of a 
leaving group is one of the main drawbacks of cross-linking agents in the past.  
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Figure 1.5 Modified nucleobases 
Modified Nucleobases 1 through 5 contain ethyl ester, methoxyethyl ester, 
methoxyphenyl ester, phenyl ester and a thioester group respectively. Modified 
nucleobase 1 is the least reactive while nucleobase 4 is the most reactive. The 
reactivity modified nucleobase 5 is difficult to compare in absence of suitable data. 
But it is more reactive than nucleobases 1 and 2 as it has an electron withdrawing 
phenyl group attached to sulfur through an ethylene bridge. These modified 
nucleobases offer a great pool of esters with varying reactivities to facilitate cross-
linking. 
The proposed modified nucleobases have all features necessary for the design of 
a cross-linking agent which can be useful for the development of an antisense 
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drug. The modified nucleobase with an ester group are designed to incorporate 
them at any position into oligodeoxynucleotide chain. The major part of an 
oligodeoxynucleotide chain can be designed with natural nucleobases to form a 
double helix with complementary DNA or mRNA fragment. The position of modified 
nucleobase in a oligonucleotide strand was defined to have adenine or guanine as 
a base complementary to it on the targeted DNA or mRNA strand. As both adenine 
and guanine have exo-amine groups, the cross-linking can happen by the attack 
of an amine nitrogen (a nucleophile) on a carbonyl carbon (an electrophile) of an 
ester group leaving alcohol as a byproduct (Scheme 1.3). 
1.4.1 The mechanism 
The proposed design (Scheme 1.3) introduces an ester group on a modified 
oligonucleotide 23 to facilitate electrophile-nucleophile interaction with 
complementary RNA 24.  Modified DNA is complementary to the targeted RNA so 
that they can form double helix selectively. After they form a double helix 
nucleophilic nitrogen of adenine on RNA, present complementary to the ester 
nucleobase would attack the carbonyl carbon making a cross-linked product 24 
with an amide bond. The byproduct alcohol will form as shown in the Scheme 1.3. 
Amide bond is known to be very stable and once it forms reaction cannot go 
backwards. Formation of an amide linkage will result into permanent bridge 
between RNA and modified DNA. 
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Many leaving groups like halides, water, tosylates etc. were considered before 
finalizing an alcohol as a leaving group. The reason for choosing an alcohol as a 
leaving group lies in the flexibility of esters. It is possible to modulate an ester group 
over the wide range of stability and selectivity using available synthetic chemistry 
methods.  
 
Scheme 1.3 Proposed cross-linking mechanism 
1.4.2 The challenge associated with their synthesis 
The success of ODN synthesis is mainly limited to unmodified ODNs. For modified 
ODNs, we still face many challenges.[75-77] In one particular case, due to the use 
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of acyl protecting groups and linkers during solid phase synthesis and their need 
of strong nucleophiles for deprotection and cleavage, many nucleophile-sensitive 
groups could not be incorporated into this highly important class of materials. 
Examples of the sensitive groups include many common ones in organic chemistry 
such as esters, alkyl halides and epoxides. The designs of modified nucleobases 
1 through 5 are very sensitive to these nucleophilic conditions.  
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Figure 1.6 Phosphoramidites for standard DNA synthesis 
The current standard DNA synthesis requires dA, dC, dG and dT 
phosphoramidites and a linker (Figure 1.6). As shown in Figure 1.6, exo-amine 
group of commercially available dA phosphoramidite is protected by benzoyl group 
26, dC phosphoramidite by benzoyl 27 or acetyl 28, dG phosphoramidite by 
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isobutyryl 29 or dimethylaminoformamidine 30 and linker contains a strong ester 
group 31.  All protecting groups and a linker are designed to sustain DNA synthesis 
conditions which vary from slightly basic to moderately acidic. These protecting 
groups can be removed only by the strong bases like ammonia or methylamine. 
Therefore, the post DNA work-up needs the use of a strong base for deprotection 
and cleavage. 
The use of strong base for post DNA synthesis work-up was the cause of concern 
as proposed nucleobases 1-5 containing variety of ester groups are not compatible 
with it. The nucleophilicity of bases used in standard DNA synthesis for work-up is 
very strong for esters to survive through the process (Scheme 1.4). The treatment 
of oligonucleotide 32 containing sensitive ester nucleobases 1-5 can easily fall off 
by the nucleophilic action of an ammonia to give ammonolyzed product 33. This 
amide has no use in the designing of cross-linking oligonucleotides. 
Therefore, to install these sensitive ester groups on oligonucleotide, needed a 
different DNA synthesis technology. Fortunately, the incorporation of sensitive 
groups into oligonucleotides has been made possible by ‘Dmoc’ oligonucleotide 
synthesis technology developed and introduced by professor Shiyue Fang.[76, 78] 
Though the stability of targeted esters using Dmoc technology was not known, the 
use of mildest possible post DNA synthesis work-up conditions and success in 
incorporation of some electrophiles into ODN,[76] made it the best choice of the 
time. 
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Scheme 1.4 Action of ammonia on the ester groups 
1.4.3 The Dmoc technology of oligonucleotide synthesis 
1.4.3.1 The synthesis 
Unlike standard DNA synthesis, Dmoc technology uses phosphoramidites 
containing nucleobases protected by Dmoc protecting group. The abbreviation 
Dmoc stands for 1,3-dithian-2-yl-methoxycarbonyl. This abbreviated form has 
been chosen for naming the technology. All nucleobases (dA, dC and dG) requiring 
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exo-amine protection were protected by Dmoc and the linker was also developed 
using Dmoc protection on a CPG solid support (Figure 1.7). The 
oligodeoxynucleotide synthesis by Dmoc technology uses standard 
oligonucleotide synthesis cycle. Along with commercially available dT 
phosphoramidite, the reagents for detritylation, coupling and oxidation remain 
same. It requires suitable capping agent to avoid problems related to cap 
exchange.  
 
Figure 1.7 Dmoc protected phosphoramidites and linker 
The major difference between standard DNA synthesis and synthesis by using 
Dmoc technology is post synthesis work-up. Standard technology uses strong 
bases like ammonia while Dmoc technology made work-up possible under nearly 
neutral conditions. 
1.4.3.2 Post synthesis work-up using Dmoc technology 
Dmoc technology carries post synthesis work-up (Scheme 1.5) in three key steps 
starting with the treatment of an oligodeoxynucleotide on CPG with 10% DBU in 
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acetonitrile 
 
Scheme 1.5 Post synthesis work-up by Dmoc technology 
. DBU being a base effects β-elimination to remove cyanoethyl group attached to 
the phosphorus backbone. In next step oxidation of all sulfurs present on Dmoc 
protections is carried out by using 0.4 M aqueous sodium periodate. Oxidation of 
sulfurs in Dmoc protecting group has been carried out to increase the acidic nature 
of tertiary proton adjacent to the sulfurs. Increased acidity of this proton then used 
to remove the protection by using 3% aqueous aniline suspension which effects 
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the cleavage and deprotection through β-elimination shown in Scheme 1.5 to give 
oligonucleotide. All steps involved in post synthesis work-up using Dmoc 
technology are conducted under nearly neutral conditions and therefore sensitive 
ester group on 34 survives in the final oligonucleotide product 35. 
 
1.5 References 
[1] S. S. Pujari, P. Leonard, F. Seela, J. Org. Chem. 2014, 79, 4423-4437. 
[2] A. M. Michelson, A. R. Todd, J. Chem. Soc. 1955, 2632-2638. 
[3] H. G. Khorana, Fed. Proc. 1971, 30, 1035. 
[4] H. G. Khorana, Chem. Ztg. 1972, 96, 642. 
[5] H. G. Khorana, Bioorg. Chem. 1978, 7, 351-393. 
[6] R. L. Letsinger, V. Mahadevan, J. Am. Chem. Soc. 1966, 88, 5319-+. 
[7] R. L. Letsinger, K. K. Ogilvie, J Am Chem Soc 1969, 91, 3350-+. 
[8] S. L. Beaucage, Tetrahedron Lett. 1984, 25, 375-378. 
[9] H. Lonnberg, Beilstein J. Org. Chem. 2017, 13, 1368-1387. 
[10] S. Aitken, E. Anderson, Nucleos. Nucleot. Nucl. 2007, 26, 931-934. 
[11] H. J. Schiller, 2004. 
[12] Anon, Org. Process Res. Dev. 2000, 4, 168-169. 
[13] W. Pieken, Ciba Found. Symp. 1997, 209, 218-223. 
[14] J. X. Tang, J. Y. Tang, American Chemical Society, 1996, pp. ORGN-118. 
[15] N. D. Sinha, Methods Mol. Biol. (Totowa, N. J.) 1993, 20, 437-463. 
[16] C. A. Stein, D. Castanotto, Mol. Ther. 2017, 25, 1069-1075. 
 22   
[17] M. L. Kelley, Z. Strezoska, K. He, A. Vermeulen, A. v. B. Smith, J. 
Biotechnol. 2016, 233, 74-83. 
[18] P. Kuhn, K. Wagner, K. Heil, M. Liss, N. Netuschil, Eng. Life Sci. 2017, 17, 
6-13. 
[19] M. Taskova, A. Mantsiou, K. Astakhova, ChemBioChem 2017, 18, 1671-
1682. 
[20] R. Suchsland, B. Appel, S. Mueller, Beilstein J. Org. Chem. 2018, 14, 397-
406. 
[21] R. E. Kohman, A. M. Kunjapur, E. Hysolli, Y. Wang, G. M. Church, Angew. 
Chem. Int. Edit. 2018, 57, 4313-4328. 
[22] L. Organick, S. D. Ang, Y. J. Chen, R. Lopez, S. Yekhanin, K. Makarychev, 
M. Z. Racz, G. Kamath, P. Gopalan, B. Nguyen, C. N. Takahashi, S. 
Newman, H. Y. Parker, C. Rashtchian, K. Stewart, G. Gupta, R. Carlson, J. 
Mulligan, D. Carmean, G. Seelig, L. Ceze, K. Strauss, Nat. Biotechnol. 
2018, 36, 660-660. 
[23] S. L. Shipman, J. Nivala, J. D. Macklis, G. M. Church, Nature (London, U. 
K.) 2017, 547, 345-349. 
[24] K. K. Chen, J. L. Kong, J. B. Zhu, N. Ermann, P. Predki, U. F. Keyser, Nano. 
Lett. 2019, 19, 1210-1215. 
[25] R. Tashiro, M. Iwamoto, H. Morinaga, T. Emura, K. Hidaka, M. Endo, H. 
Sugiyama, Nucleic Acids Res. 2015, 43, 6692-6700. 
[26] R. K. O'Reilly, A. J. Turberfield, T. R. Wilks, Acc. Chem. Res. 2017, 50, 
2496-2509. 
[27] H. G. Khorana, Chimia 1979, 33, 252-252. 
[28] C. R. Millan, F. J. Acosta-Reyes, L. Lagartera, G. U. Ebiloma, L. Lemgruber, 
J. J. Nue Martinez, N. Saperas, C. Dardonville, H. P. de Koning, J. L. 
Campos, Nucleic Acids Res. 2017, 45, 8378-8391. 
[29] R. Christova, Adv. Protein Chem. Str. 2013, 91, 101-133. 
[30] T.-K. Huang, H. Puchta, Plant Cell Rep. 2019, 38, 443-453. 
[31] K. Selle, R. Barrangou, J. Food Sci. 2015, 80, R2367-R2372. 
[32] A. M. Krichevsky, E. J. Uhlmann, Neurotherapeutics 2019, 16, 319-347. 
 23   
[33] C. Mayer, G. R. McInroy, P. Murat, P. Van Delft, S. Balasubramanian, 
Angew. Chem. Int. Edit. 2016, 55, 11144-11148. 
[34] L. Li, J. Yang, J. Wang, J. Kopecek, ACS Nano. 2018, 12, 3658-3670. 
[35] B. J. Evison, M. L. Actis, N. Fujii, Bioorg. Med. Chem. 2016, 24, 1071-1078. 
[36] L. Li, J. Yang, J. Wang, J. Kopecek, J. Drug Targeting 2019, 27, 566-572. 
[37] S. Andersson, M. Antonsson, M. Elebring, R. Jansson-Loefmark, L. 
Weidolf, Drug Discovery Today 2018, 23, 1733-1745. 
[38] Y. Sugihara, S. Tatsumi, A. Kobori, Chem. Lett. 2017, 46, 236-239. 
[39] W. Copp, D. K. O'Flaherty, C. J. Wilds, Org. Biomol. Chem. 2018, 16, 9053-
9058. 
[40] H.-J. Feng, Y.-L. Bao, Z.-P. Liang, F.-P. Zhao, S.-E. Xu, W. Xu, C. Zhao, G. 
Qin, Int. J. Oncol. 2017. 
[41] M. Georgieva, N. M. Rashydov, M. Hajduch, DNA Repair 2017, 50, 14-21. 
[42] S. Najah, C. Saulnier, J. L. Pernodet, S. Bury-Mone, Bmc. Biotechnol. 2019, 
19. 
[43] C. Curtin, T. Cordente, Microb. Cell 2016, 3, 1-U6. 
[44] D. Lochmann, E. Jauk, A. Zimmer, Eur. J. Pharm. Biopharm. 2004, 58, 237-
251. 
[45] S. Andersson, M. Antonsson, M. Elebring, R. Jansson-Lofmark, L. Weidolf, 
Drug Discovery Today 2018, 23, 1733-1745. 
[46] K. Pant, B. Anderson, H. Perdana, M. A. Malinowski, A. T. Win, C. Pabst, 
M. C. Williams, R. L. Karpel, PLoS One 2018, 13, e0194357/0194351-
e0194357/0194323. 
[47] P. G. Penketh, E. Patridge, K. Shyam, R. P. Baumann, R. Zhu, K. Ishiguro, 
A. C. Sartorelli, Chem. Res. Toxicol. 2014, 27, 1440-1449. 
[48] R. Wheeler, Wikimedia Commons 2007, Transferred from en.wikipedia to 
Commons., 
https://commons.wikimedia.org/wiki/File:Lambda_repressor_1LMB.png, 
https://commons.wikimedia.org/wiki/File:EcoRV_1RVA.png. 
[49] T. Splettstoesser, Wikimedia Commons 2011, Own work, 
https://commons.wikimedia.org/wiki/File:Nucleosome1.png. 
 24   
[50] M. Amouyal, Front. Genet. 2014, 5. 
[51] M. Zahran, I. Daidone, J. C. Smith, P. Imhof, Journal of Molecular Biology 
2010, 401, 415-432. 
[52] B. Dey, S. Thukral, S. Krishnan, M. Chakrobarty, S. Gupta, C. Manghani, 
V. Rani, Mol. Cell. Biochem. 2012, 365, 279-299. 
[53] Y. Dai, J. Kennedy-Darling, M. R. Shortreed, M. Scalf, A. P. Gasch, L. M. 
Smith, Anal. Chem. (Washington, DC, U. S.) 2017, 89, 7841-7846. 
[54] A. N. Sexton, M. Machyna, M. D. Simon, Methods Mol. Biol. (N. Y., NY, U. 
S.) 2016, 1480, 87-97. 
[55] T. Schneider-Poetsch, M. Yoshida, Annu. Rev. Biochem 2018, 87, 391-420. 
[56] J. R. Tietjen, L. J. Donato, D. Bhimisaria, A. Z. Ansari, Methods in 
Enzymology, Vol 497: Synthetic Biology, Methods for Part/Device 
Characterization and Chassis Engineering, Pt A 2011, 497, 3-30. 
[57] P. G. Sveshnikov, I. D. Grozdova, M. V. Nesterova, E. S. Severin, Protein 
Kinase a and Human Disease 2002, 968, 158-172. 
[58] T. Carell, C. Brandmayr, A. Hienzsch, M. Muller, D. Pearson, V. Reiter, I. 
Thoma, P. Thumbs, M. Wagner, Angew. Chem. Int. Edit. 2012, 51, 7110-
7131. 
[59] T. Kawasaki, F. Nagatsugi, M. M. Ali, M. Maeda, K. Sugiyama, K. Hori, S. 
Sasaki, J. Org. Chem. 2005, 70, 14-23. 
[60] A. L. Rozelle, R. N. Kumar, S. Lee, Nucleos. Nucleot. Nucl. 2019, 38, 236-
247. 
[61] U. Galderisi, M. Cipollaro, A. Cascino, Expert Opin. Ther. Pat. 2001, 11, 
1605-1611. 
[62] S. Sasaki, Chem. Pharm. Bull. (Tokyo) 2019, 67, 505-518. 
[63] K. Yamada, Y. Abe, H. Murase, Y. Ida, S. Hagihara, F. Nagatsugi, J. Org. 
Chem. 2018, 83, 8851-8862. 
[64] M. M. Soldevilla, H. Villanueva, N. Casares, J. J. Lasarte, M. Bendandi, S. 
Inoges, A. L. D. de Cerio, F. Pastor, Oncotarget 2016, 7, 23182-23196. 
[65] J. N. Buxbaum, New Engl. J. Med. 2018, 379, 82-85. 
[66] D. R. Corey, Nat. Neurosci. 2017, 20, 497-499. 
 25   
[67] J. Jakubovska, D. Tauraite, R. Meskys, Sci. Rep. 2018, 8, 16484. 
[68] N. De Laet, A. Madder, J. Photochem. Photobiol., A 2016, 318, 64-70. 
[69] J. Sun, X. Tang, Sci Rep 2015, 5, 10473. 
[70] S. Imoto, T. Chikuni, H. Kansui, T. Kunieda, F. Nagatsugi, Nucleos. Nucleot. 
Nucl. 2012, 31, 752-762. 
[71] Y. Yoshimura, K. Fujimoto, Org. Lett. 2008, 10, 3227-3230. 
[72] K. Yamada, Y. Abe, F. Nagatsugi, Curr. Protoc. Nucleic Acid Chem. 2019, 
77, 79. 
[73] S. Hagihara, W. C. Lin, S. Kusano, X. G. Chao, T. Hori, S. Imoto, F. 
Nagatsugi, Chembiochem 2013, 14, 1427-1429. 
[74] K. Kramer, T. Sachsenberg, B. M. Beckmann, S. Qamar, K.-L. Boon, M. W. 
Hentze, O. Kohlbacher, H. Urlaub, Nat. Methods 2014, 11, 1064-1070. 
[75] M. N. K. Meher G, Iyer R. P. , Curr. Protoc. Nucleic Acid Chem. 2017, 69, 
2.1.1-2.1.40. 
[76] X. Lin, J. S. Chen, S. Shahsavari, N. Green, D. Goyal, S. Y. Fang, Org. Lett.  
2016, 18, 3870-3873. 
[77] T. J. Matray, M. M. Greenberg, J. Am. Chem. Soc. 1994, 116, 6931-6932. 
[78] S. Shahsavari, X. Lin, J. S. Chen, N. Green, D. Goyal, S. Y. Fang, Abstr. 
Pap. Am. Chem. Soc. 2017, 253. 
 
 26   
2 Synthesis of modified nucleobases 
2.1 Introduction 
Oligonucleotide cross-linking agents have the potential to be a next generation 
antisense drug. Reported ross-linking agents known to have several limitations to 
use them as antisense drugs.[1, 2] We have designed oligonucleotide cross-linking 
agents which can potentially overcome those limitations and serve the purpose. 
To synthesize oligonucleotides with cross-linking features we used Dmoc 
oligonucleotide synthesis technology. To accomplish the goal, we synthesized 
modified nucleobase phosphoramidites 1-4 with ester group and 5 with a thioester 
group. Also, we synthesized Dmoc protected standard phosphoramidites 7-9 and 
a linker 10 (Figure 2.1). This chapter is focused on the synthesis and 
characterization of these compounds. 
2.2 Results and discussion 
The synthesis started with the synthesis of compound 36 according to reported 
procedure.[3, 4] Cross-coupling of 36 with the commercially available 2-(ethoxy-
carbonyl)ethylzinc bromide 37 using a palladium catalyst gave 38 containing one 
of the desired esters.[5] The other ester-containing monomers 2-5 were 
synthesized from 38.[6] Hydrolysis of 38 under basic conditions gave the nucleoside 
carboxylic acid 39. Hydrolysis conditions were defined through trial and errors to 
ensure the stability of glyosidic bond. Coupling 39 with the  
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Figure 2.1 Modified and Dmoc nucleobase phosphoramidites, and linker 
alcohols 40a-40c and the thiol 40d gave the esters 41a-41c and the thioester 41d, 
respectively. Removing the silyl protecting groups of 38 and 41a-41d using TBAF 
gave 42a-42e. Removal of silyl protecting group from 41a-41d by TBAF at room 
temperature was destroying all the starting materials and resulting into very 
complex reaction mixture without the traces of products. Other deprotecting  
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Scheme 2.1 Synthesis of modified nucleobases 1-5 
agents like triethylamine hydrofluoride, pyridine hydrofluoride were tried but either 
they were slow or yielding the similar results. Finally, carrying deprotection strictly 
under 0 ºC and performing quick purification using neutralized silica gel worked. 
The yields obtained by this way were close to 100% in all cases. Later, compound 
38 was found to was found to be synthesized with better results under these 
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conditions. Selective tritylation of the primary hydroxyl group of 42a-42e using 
DMTr-Cl gave 43a-43e. This was again found to be working differently for different 
monomers. 
For the substrates 42a and 42b tritylation was smooth but other substrates needed 
special precautions to perform column chromatography for their purification. 
Ensuring neutralization of silica gel and quick purifications solved the problems to 
get desired products in other cases. Converting 43a-43e to the ester-containing 
phosphoramidite monomers 1-5 was achieved using the phosphitylation reagent 
2-cyanoethyl N,N,N',N'-tetraisopropylphosphordiamidite and an activator 
diisopropylammonium tetrazolide.[32]  
Dmoc protected phosphoramidites 7-9 and linker 10 (Figure 2.1) were synthesized 
using procedures developed previously by our group with slight modifications for 
dG-Dmoc phosphoramidite 9.[7]  
Synthesis of Dmoc-dA-phosphoramidite 7 was accomplished in four steps 
(Scheme 2.2); compound 44 was protected by Dmoc successfully by treating it first 
with LDA using THF as a solvent below -78 ºC for 30 minutes followed by addition 
of 45 and stirring the reaction overnight at room temperature to give 47. Compound 
45 was then treated with TBAF for 2 hours in THF to deprotect TBS groups and 
selective tritylation of deprotected product was carried using DMTr-Cl, pyridine as 
a solvent and stirring the reaction mixture at room temperature for 8 hours to get 
47. The phosphitylation of 47 using DCM as a solvent, 2-cyanoethyl N,N,N',N'-
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tetraisopropylphosphordiamidite and 1H-tetrazole was conducted to obtain 7. 
 
Scheme 2.2 Synthesis of dA and dC-Dmoc-phosphoramidite 
Synthesis of Dmoc-dC-phosphoramidite 8 (Scheme 2.2) was completed in four 
steps using identical conditions used for the synthesis of 7. 
For the synthesis of Dmoc-dG-phosphoramidite 9 (Scheme 2.3) route was slightly 
modified for the first step compared to compounds 7 and 8. Before Dmoc 
protection step carbonyl oxygen of 51 was temporarily protected to facilitate 
selective protection of an exo-amine group. The rest of the steps were same to the 
ones used for the synthesis of compounds 7 and 8. 
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Scheme 2.3 Synthesis of dG-Dmoc-phosphoramidite and Dmoc linker 
Synthesis of a linker 10 needed six steps (Scheme 2.3). To make 56, 1,3-dithiane 
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54 was first deprotonated by using t-butyl lithium in THF under -78 ºC for 1 hour 
followed by addition of 55 and subsequent stirring by another hour. Compound 56 
then converted 57 in two steps; 1) 56 was treated with calcium hydride and 
carbonyl diimidazole in THF for 8 hours to get an intermediate product. 2) The 
intermediate was then treated with DBU, DMTr-dT in THF for 8 hours to get 
compound 57. TBS deprotection of 57 using TBAF followed by coupling with 
succinic anhydride gave compound 58. Compound 58 was then attached to CPG 
through DCC coupling over hours to get 10 as a final linker. 
2.3 Experimental section 
2.3.1 General experimental  
All reactions were performed in oven-dried glassware under argon using standard 
Schlenk techniques. Reagents and solvents available from commercial sources 
were used as received unless otherwise noted. THF and DCM were dried using 
an Innovative Technology Pure-Solv™ system. Pyridine was distilled over CaH2 
under nitrogen. Thin layer chromatography (TLC) was performed using Sigma-
Aldrich TLC plates, silica gel 60F-254 over glass support, 250 μm thickness. Flash 
column chromatography was performed using SiliCycle silica gel, particle size 40-
63 μm. 1H and 13C NMR spectra were measured on a Varian UNITY INOVA 
spectrometer at 400 and 100 MHz, respectively; chemical shifts (δ) were reported 
in reference to solvent peaks (residue CHCl3 at δ 7.26 ppm for 1H and CDCl3 at δ 
77.00 ppm for 13C). HRMS was obtained on a Thermo HR-Orbitrap Elite Mass 
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Spectrometer. 
2.3.2 Synthesis of modified monomers 1-5 
Synthesis of modified monomers 1-5 was accomplished according to the Scheme 
2.1 as follows; 
Compound 38: Compound 36 (5.00 g, 10.02 mmol, 1.0 equiv.), synthesized 
according to reported procedure, [29-30] was dissolved in anhydrous DMF (20 mL) 
in a two-necked round-bottomed flask under argon. Commercially available 3-
ethoxy-3-oxopropylzinc bromide 37 (0.5 M in THF, 30.08 mL, 15.04 mmol, 1.5 
equiv.) was added via a syringe, and bis(triphenylphosphine)palladium(II) 
dichloride [(Ph3P)2PdCl2 (140 mg, 0.20 mmol, 0.02 equiv.] was added under 
positive argon pressure. The reaction mixture was stirred at 80 ºC for 30 min. After 
cooling to r.t., EtOAc (150 mL) and sat. NaHCO3 (50 mL) was added sequentially. 
The mixture was partitioned. The organic layer was washed with sat. NaCl (50 mL 
x 4), dried over anhydrous NaSO4, filtered and evaporated to dryness under 
reduced pressure. Purification with flash chromatography (SiO2, hexanes/EtOAc 
6:1 to 5:2) gave compound 38 as a colorless oil (4.32 g, 76%): TLC Rf = 0.58 
(hexanes/EtOAc 3:2); 1H NMR (400 MHz, CDCl3) δ 8.85 (s, 1H), 8.33 (s, 1H), 6.53 
(t, J = 6.4 Hz, 1H), 4.65 (m, 1H), 4.16 (q, J = 7.1 Hz, 2H), 4.04 (q, J = 3.3 Hz, 1H), 
3.89 (dd, J = 4.2, 11.2 Hz, 1H), 3.79 (dd, J = 3.2, 11.2 Hz, 1H),  3.56 (t, J = 7.3 Hz, 
2H), 2.99 (t, J = 7.0 Hz, 2H),  2.72 (m, 1H), 2.47 (m, 1H), 1.24 (t, J = 7.1 Hz, 2H), 
0.92 (s, 9H), 0.90 (s, 9H), 0.11 (s, 6H), 0.08 (s, 3H), 0.07 (s, 3H) ppm; 13C NMR 
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(100 MHz, CDCl3) δ 172.8, 160.6, 152.3, 150.3, 142.5, 133.3, 88.2, 84.6, 72.2, 
63.0, 41.3, 31.7, 28.0, 26.1, 25.9, 18.6, 18.2, 14.3, -4.4, -4.5, -5.1, -5.2 ppm; HRMS 
(ESI): calcd for C27H48N4O5Si2H [M+H]+ 565.32415 found 565.32319, and 
C27H48N4O5Si2Na [M+Na]+ 587.30609 found 587.30453. 
Compound 39: Compound 38 (3.5 g, 6.20 mmol, 1.0 equiv.) and finely grounded 
NaOH (2.05 g, 1.15 mmol, 8.25 equiv.) in THF and H2O (v/v 20:1) were stirred at 
r.t. for 16 h. The reaction mixture was cooled on an ice bath and quenched with 
citric acid (4.0 g). EtOAc (100 mL) was added and the mixture was partitioned. The 
organic phase was washed with sat. NaCl (50 mL x 3), dried over anhydrous 
Na2SO4, filtered and evaporated to dryness under reduced pressure. Purification 
with flash chromatography (SiO2, DCM/AcOH/MeOH 100:1:0 to 100:1:2) gave 39 
as a colorless oil (2.85 g, 86%): TLC Rf = 0.36 (DCM/AcOH/MeOH 10:0.1:0.4 ); 1H 
NMR (400 MHz, CDCl3) δ 8.86 (s, 1H), 8.43 (s, 1H), 6.51 (t, J = 6.4 Hz, 1H), 4.63 
(m, 1H), 4.03 (q, J = 3.2 Hz, 1H), 3.88 (dd, J = 4.1, 11.2 Hz, 1H), 3.77 (dd, J = 3.1, 
11.2 Hz, 1H),  3.58 (t, J = 7.1 Hz, 2H), 2.98 (t, J = 6.8 Hz, 2H),  2.68 (m, 1H), 2.48 
(m, 1H), 0.89 (s, 9H), 0.87 (s, 9H), 0.08 (s, 6H), 0.06 (s, 3H), 0.05 (s, 3H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 175.3, 160.3, 151.8, 150.3, 143.2, 132.6, 88.3, 84.8, 
72.1, 62.9, 41.5, 32.4, 27.5, 26.2, 26.0, 18.7, 18.3, -4.2, -4.4, -5.0, -5.1 ppm; HRMS 
(ESI): calcd for C25H44N4O5Si2H [M+H]+ 537.29285 found 537.29200, and 
C25H44N4O5Si2Na [M+Na]+ 559.27479 found 559.27328. 
General procedure for converting 39 to 41a-41d: Compound 39 (600 mg, 1.12 
mmol, 1.0 equiv.) in anhydrous DCM (50 mL) was cooled to 0 ºC. 1-(3-
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Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl, 257 mg, 1.34 
mmol, 1.2 equiv.) was added. After stirring at 0 ºC for 20 min, 1-
hydroxybenzotriazole hydrate (HOBt, 38 mg, 0.28 mmol, 0.25 equiv.) was added, 
and stirring was continued for 20 min at 0 ºC. Compound 40a (133 µL, 1.68 mmol, 
1.5 equiv.), 40b (209 mg, 1.68 mmol, 1.5 equiv.), 40c (158 mg, 1.68 mmol, 1.5 
equiv.) or 40d (226 µL, 1.68 mmol, 1.5 equiv.)  was then added. After stirring at r.t. 
for 12 h, the mixture was transferred to a separatory funnel and washed with sat. 
NaCl (15 mL x 3). The organic layer was dried over anhydrous Na2SO4, filtered, 
and evaporated to dryness. The products were purified with flash chromatography 
to give 41a-41d, respectively.  
Compound 41a: Flash chromatography (SiO2, hexanes/EtOAc 5:1 to 3:1) gave 
41a as a thick oil (510 mg, 77%): TLC Rf = 0.51 (hexanes/EtOAc 2:1); 1H NMR 
(400 MHz, CDCl3) δ 8.82 (s, 1H), 8.32 (s, 1H), 6.51 (t, J = 6.5 Hz, 1H), 4.63 (m, 1H 
), 4.23 (m, 2H), 4.03 (q, J = 3.2 Hz, 1H), 3.87 (dd, J = 4.2, 11.2 Hz, 1H), 3.77 (dd, 
J = 3.2, 11.2 Hz, 1H), 3.57-3.51 (m, 4H), 3.34 (s, 3H),  3.04 (t, J = 7.5 Hz, 2H), 
2.70 (m, 1H), 2.46 (m, 1H), 0.90 (s, 9H), 0.89 (s, 9H), 0.09 (s, 6H), 0.07 (s, 3H), 
0.06 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.6, 160.3, 152.1, 150.1, 142.4, 
133.1, 88.1, 84.5, 72.1, 70.5, 63.7, 62.9, 59.0, 41.3, 31.5, 27.9, 26.1, 25.9, 25.8, 
18.6, 18.2, -4.4, -4.5, -5.1, -5.2 ppm; HRMS (ESI): calcd for C28H50N4O6Si2H 
[M+H]+ 595.33472 found 595.33371, and C28H50N4O6Si2Na [M+Na]+ 617.31666 
found 617.61455. 
Compound 41b: Flash chromatography (SiO2, hexanes/EtOAc 5:1 to 3:1) gave 
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41b as a thick oil (508 mg, 71%): TLC Rf = 0.55 (hexanes/EtOAc 2:1); 1H NMR 
(400 MHz, CDCl3) δ 8.88 (s, 1H), 8.35 (s, 1H), 7.00 (m, 2H ), 6.87 (m, 2H ),  6.53 
(t, J = 6.4 Hz, 1H), 4.65 (m, 1H ), 4.04 (q, J = 3.3 Hz, 1H), 3.89 (dd, J = 4.2, 7.0 
Hz, 1H), 3.78-3.75 (m, 4H),  3.67 (t, J = 7.2 Hz, 2H), 3.23 (m, 2H),  2.72 (m, 1H), 
2.48 (m, 1H), 0.91 (s, 9H), 0.90 (s, 9H), 0.11 (s, 6H), 0.08 (s, 3H), 0.07 (s, 3H) 
ppm; 13C NMR (100 MHz, CDCl3) δ 171.6, 160.0, 157.1, 152.2, 150.2, 144.3, 
142.5, 133.2, 122.3, 114.4, 88.1, 84.6, 72.1, 62.9, 55.7, 41.4, 31.7, 28.0, 26.2, 
26.0, 18.6, 18.2, -4.3, -4.4, -5.0, -5.1 ppm; HRMS (ESI): calcd for C32H50N4O6Si2H 
[M+H]+ 643.33471 found 643.33390, and C32H50N4O6Si2Na [M+Na]+ 665.31666 
found 665.31467. 
Compound 41c: Flash chromatography (SiO2, hexanes/EtOAc 5:1 to 3:1) gave 
41c as a thick oil (495 mg, 72%): TLC Rf = 0.63 (hexanes/EtOAc 2:1); 1H NMR 
(400 MHz, CDCl3) δ 8.87(s, 1H), 8.34 (s, 1H), 7.35 (t, J = 7.6 Hz, 2H ), 7.19 (t, J = 
7.1 Hz, 1H ), 7.07 (d, J = 8.0 Hz, 2H ), 6.52 (t, J = 6.5 Hz, 1H), 4.63 (m, 1H), 4.03 
(m, 1H), 3.88 (dd, J = 3.9, 11.2 Hz, 1H), 3.78 (dd, J = 2.6, 11.1 Hz, 1H),  3.67 (t, J 
= 7.1 Hz, 2H), 3.24 (t, J = 7.2 Hz, 2H),  2.70 (m, 1H), 2.47 (m, 1H), 0.90 (s, 9H), 
0.89 (s, 9H), 0.09 (s, 6H), 0.07 (s, 6H) ppm; 13C NMR (100 MHz, CDCl3) δ 171.4, 
160.1, 152.3, 150.9, 150.4, 142.7, 133.3, 129.5, 125.8, 121.7, 88.2, 84.6, 72.1, 
62.9, 41.4, 31.7, 27.9, 26.1, 25.9, 18.6, 18.2, -4.4, -4.5, -5.1, -5.2 ppm; HRMS 
(ESI): calcd for C31H48N4O5Si2H [M+H]+ 613.32415 found 613.32328, and 
C31H48N4O5Si2Na [M+Na]+ 635.30609 found 635.30441. 
Compound 41d: Flash chromatography (SiO2, hexanes/EtOAc 5:1 to 3:1) gave 
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41d as a thick oil (560 mg, 74%): TLC Rf = 0.81 (hexanes/EtOAc 3:2); 1H NMR 
(400 MHz, CDCl3) δ 8.82(s, 1H), 8.32 (s, 1H), 7.27-7.16 (m, 5H ), 6.50 (t, J = 6.5 
Hz, 1H ), 4.63 (m, 1H), 4.02 (q, J = 3.3 Hz, 1H), 3.87 (dd, J = 4.2, 11.2 Hz, 1H), 
3.77 (dd, J = 3.2, 11.2 Hz, 1H),  3.57 (t, J = 7.3 Hz, 2H), 3.25 (t, J = 7.8 Hz, 2H),  
3.11 (t, J = 7.2 Hz, 2H), 2.84 (t, J = 8.2 Hz, 2H), 2.70 (m, 1H), 2.46 (m, 1H), 0.90 
(s, 9H), 0.88 (s, 9H), 0.09 (s, 6H), 0.06 (s, 3H), 0.05 (s, 3H) ppm; 13C NMR (100 
MHz, CDCl3) δ 197.7, 159.9, 152.1, 150.2, 142.4, 139.9, 133.0, 128.5, 128.4, 
126.4, 88.0, 84.4, 72.1, 62.9, 41.3, 41.1, 36.0, 30.4, 28.2, 26.1, 25.9, 18.6, 18.1, -
4.4, -4.5, -5.1, -5.2 ppm; HRMS (ESI): calcd for C33H52N4O4SSi2H [M+H]+ 
657.33260 found 657.33026. 
General procedure for converting 38 and 41a-41d to 42a-42e: Compound 38 
(700 mg, 1.24 mmol, 1.0 equiv.), 41a (510 mg, 0.86 mmol, 1.0 equiv.), 42b (495 
mg, 0.77 mmol, 1.0 equiv.), 42c (490 mg, 0.80 mmol, 1.0 equiv.) or 42d (550 mg, 
0.82 mmol, 1.0 equiv.) in anhydrous THF (20 mL) was cooled on an ice bath. A 
solution of tetrabutylammonium fluoride (TBAF) in THF (1.0 M, 2.5 equiv.) was 
added via a syringe dropwise. After stirring at 0 °C for 2.5 h, volatiles were removed 
under reduced pressure. The products were purified with flash chromatography to 
give 42a-42e, respectively.  
Compound 42a: Flash chromatography (SiO2, DCM/MeOH 100:2 to 100:7) gave 
12a as a colorless oil (410 mg, 98%): TLC Rf = 0.35 (DCM/MeOH 10:1); 1H NMR 
(400 MHz, CDCl3) δ 8.83 (s, 1H), 8.10 (s, 1H), 6.41 (q, J = 5.5 Hz, 1H ), 5.82 (d, 
10.4 Hz, 1H), 4.82 (d, 5.0 Hz, 1H), 4.23 (s, 1H), 4.15 (q, J = 7.2 Hz, 2H ), 3.99 (d, 
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13.7 Hz, 1H), 3.84 (t, J = 11.1 Hz, 1H), 3.57 (m, 2H), 3.14 (m, 1H), 3.01 (m, 2H), 
2.37 (m, 1H), 1.24 (t, J = 7.1 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.9, 
162.3, 151.8, 149.7, 143.9, 134.8, 90.0, 88.1, 73.9, 63.9, 61.0, 41.2, 31.8, 28.4, 
14.7 ppm; HRMS (ESI): calcd for C15H20N4O5H [M+H]+ 337.15119 found 
337.15058, and C15H20N4O5Na [M+Na]+ 359.13314 found 359.13194. 
Compound 42b: Flash chromatography (SiO2, DCM/MeOH 100:2 to 100:7) gave 
42b as a colorless oil (310, 99%): TLC Rf = 0.47 (DCM/MeOH 10:1); 1H NMR (400 
MHz, CDCl3) δ  8.81 (s, 1H), 8.14 (s, 1H), 6.42 (q, J = 3.6 Hz, 1H), 4.79 (d, J = 3.8 
Hz, 1H), 4.23-4.21 (m, 3H), 3.97 (d, J = 12.7 Hz, 1H), 3.81-3.79 (m, 1H), 3.57-3.52 
(m, 4H), 3.35 (s, 3H), 3.06-3.02 (m, 3H), 2.37 (q, J = 5.7 Hz, 1H) ppm; 13C NMR 
(100 MHz, CDCl3) δ 172.3, 161.4, 151.1, 149.1, 143.3, 134.1, 89.2, 87.3, 72.9, 
70.2, 63.5, 63.1, 58.7, 40.6, 30.9, 27.6 ppm; HRMS (ESI): calcd for C16H22N4O6H 
[M+H]+ 367.16176 found 367.16106, and C16H22N4O6Na [M+Na]+ 389.14370 found 
389.14235. 
Compound 42c: Flash chromatography (SiO2, EtOAc/acetone 10:1 to 10:5) gave 
42c as colorless oil (300 mg, 94%): TLC Rf = 0.37 (EtOAc/acetone 1:1); 1H NMR 
(400 MHz, CDCl3) δ 8.87 (s, 1H), 8.23 (s, 1H), 6.99 (d, J = 9.2 Hz, 2H), 6.87 (d, J 
= 9.2 Hz, 2H), 6.41-6.33 (m, 1H), 4.81 (d, J = 5.0 Hz, 1H), 4.41 (q, J = 3.7 Hz, 1H), 
3.99 (d, J = 12.0 Hz, 1H), 3.77 (s, 3H), 3.67-3.64 (m, 2H), 3.25-3.22 (m, 2H), 3.12-
3.02 (m, 1H), 2.63 (d, J = 15.2 Hz, 1H), 2.37 (dd, J = 6.2, 13.7 Hz, 1H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 171.6, 161.5, 157.2, 151.5, 151.4, 144.5, 144.2, 143.6, 
122.3, 114.4, 89.9, 89.6, 63.5, 63.5, 55.7, 40.9, 31.4, 28.0 ppm; HRMS (ESI): calcd 
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for C20H22N4O6H [M+H]+ 415.16176 found 415.16118, C20H22N4O6Na [M+Na]+ 
437.14370 found 437.14251. 
Compound 42d: Flash chromatography (SiO2, EtOAc/acetone 10:1 to 10:5) gave 
42d as colorless oil (292 mg, 95%): TLC Rf = 0.40 (EtOAc/acetone 1:1); 1H NMR 
(400 MHz, CDCl3) δ 8.87 (s, 1H), 8.12 (s, 1H), 7.36 (t, J = 7.5 Hz, 2H), 7.21 (t, J = 
7.4 Hz, 1H), 7.08-7.05 (m, 2H), 6.42 (q, J = 3.7 Hz, 1H), 4.80 (d, 4.9 Hz, 1H), 3.99 
(d, 13.1 Hz, 1H), 3.83 (t, 11.4 Hz, 2H), 3.69 (m, 2H), 3.56 (t, 7.4 Hz, 1H), 3.29-3.24 
(m, 2H), 3.11-2.97 (m, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 171.2, 161.4, 151.5, 
151.4, 150.7, 143.7, 134.4, 129.4, 125.8, 121.5, 89.6, 87.7, 73.4, 63.5, 40.9, 31.4, 
27.9 ppm; HRMS (ESI): calcd for C19H20N4O5H [M+H]+ 385.15119 found 
385.15057, and C19H20N4O5Na [M+Na]+ 407.13314 found 407.13234. 
Compound 42e: Flash chromatography (SiO2, EtOAc/MeOH 100:1 to 100:5) gave 
42e as a colorless oil (335 mg, 92%): TLC Rf = 0.51 (EtOAc/MeOH 10:1); 1H NMR 
(400 MHz, CDCl3) δ 8.82 (s, 1H), 8.15 (s, 1H), 7.29-7.25 (m, 2H), 7.21-7.17 (m, 
3H), 6.43 (q, J = 3.5 Hz, 1H), 4.81 (d, J = 5.0 Hz, 1H), 4.23 (s, 1H), 3.99 (dd, J = 
1.6, 12.8 Hz, 1H), 3.58 (t, J = 7.3 Hz, 2H), 3.27 (t, J = 7.4 Hz, 2H), 3.13-3.02 (m, 
4H), 2.85 (t, J = 8.1 Hz, 2H), 2.39 (q, J = 5.4 Hz, 1H) ppm; 13C (100 MHz, CDCl3) 
δ 197.9, 161.3, 151.5, 149.4, 143.7, 139.8, 134.3, 128.5, 128.4, 126.5, 89.5, 87.6, 
73.2, 63.4, 40.9, 35.9, 30.5, 28.2 ppm; HRMS (ESI): calcd for C21H24N4O4SH 
[M+H]+ 429.15965 found 429.15810. 
General procedure for converting 42a-42e to 43a-43e: To compound 42a (400 
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mg, 1.19 mmol, 1.0 equiv.), 42b (310 mg, 0.85 mmol, 1.0 equiv.), 42c (300 mg, 
0.72 mmol, 1.0 equiv.), 42d (290 mg, 0.75 mmol, 1.0 equiv.), or 42e (330 mg, 0.74 
mmol, 1.0 equiv.) in freshly distilled pyridine (15 mL) was added 4,4-dimethoxytrityl 
chloride (DMTr-Cl, 1.1 equiv.) with rigorous stirring at r.t. under positive argon 
pressure. The reaction was allowed to proceed at r.t. for 8 h. Volatiles were 
removed under reduced pressure. The products were purified with flash 
chromatography to give 43a-43e, respectively. 
Compound 43a: Flash chromatography (SiO2, DCM/MeOH/Et3N 100:0:4 to 
100:3:4) gave 43a as a white foam (668 mg, 88%): TLC Rf = 0.65 (DCM/MeOH 
100:6); 1H NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 8.15 (s, 1H), 7.38 – 7.36 (m, 
2H), 7.27 – 7.16 (m, 7H), 6.79 (d, J = 8.8 Hz, 4H), 6.48 (t, J = 6.5 Hz, 1H), 4.68 (s, 
1H), 4.15 – 4.08 (m, 3H), 3.76 (s, 6H), 3.52 (t, J = 7.4 Hz, 2H), 3.43-3.35 (m, 2H), 
2.97 (t, J = 7.4 Hz, 2H), 2.88-2.81 (m, 1H), 2.55 – 2.49 (m, 1H), 1.21 (t, J = 7.1 Hz, 
3H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.5, 160.4, 158.4, 152.0, 149.9, 144.3, 
142.2, 135.4, 135.4, 133.0, 129.8, 127.9, 127.7, 126.8, 113.0, 86.4, 85.9, 84.2, 
72.4, 63.6, 60.3, 55.0, 39.9, 31.3, 27.7, 14.0 ppm; HRMS (ESI): calcd for 
C36H38N4O7H [M+H]+ 639.28187 found 639.28000. 
Compound 43b: Flash chromatography (SiO2, (DCM/MeOH/Et3N 100:0:4 to 
100:3:4) gave 43b as a white foam (530 mg, 94%): TLC Rf = 0.62 (DCM/MeOH 
100:6); 1H NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 8.14 (s, 1H), 7.41 – 7.35 (m, 
2H), 7.30 – 7.16 (m, 7H), 6.79 (d, J = 8.7 Hz, 4H), 6.48 (t, J = 6.5 Hz, 1H), 4.69 – 
4.66 (m, 1H), 4.22 – 4.19 (m, 2H), 4.14 – 4.11 (m, 1H), 3.76 (s, 6H), 3.58 – 3.49 
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(m, 4H), 3.43 – 3.37 (m, 2H), 3.33 (s, 3H), 3.03 (t, J = 7.4 Hz, 2H), 2.88-2.81 (m, 
1H), 2.56-2.49 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.7, 160.4, 158.5, 
152.2, 150.1, 144.4, 142.3, 135.6, 135.6, 133.2, 130.0, 128.1, 127.9, 127.0, 113.2, 
86.7, 86.1, 84.4, 72.7, 70.5, 63.9, 63.7, 59.1, 55.3, 40.2, 31.5, 27.9 ppm; HRMS 
(ESI): calcd for C37H40N4O8H [M+H]+ 669.29244 found 669.29233, and 
C37H40N4O8Na [M+Na]+ 691.27438 found 691.27271. 
Compound 43c: Flash chromatography (SiO2, EtOAc/acetone/Et3N 100:10:4 to 
100:50:6) gave 43c as a white foam (425 mg, 82%): TLC Rf = 0.68 (EtOAc/acetone 
5:3); 1H NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 8.16 (s, 1H), 7.39 – 7.35 (m, 2H), 
7.31 – 7.15 (m, 7H), 6.99 – 6.94 (m, 2H), 6.85 – 6.74 (m, 6H), 6.49 (t, J = 6.5 Hz, 
1H), 4.70 (m, 1H), 4.15 (q, J = 4.9 Hz, 1H), 3.80 – 3.70 (m, 9H), 3.64 (t, J = 7.3 Hz, 
2H), 3.40 (t, J = 4.7 Hz, 2H), 3.21 (t, J = 7.3 Hz, 2H), 2.88 – 2.82 (m, 1H), 2.56-
2.50 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ 171.6, 160.1, 158.5, 157.1, 152.2, 
150.1, 144.4, 144.2, 142.4, 135.6, 135.6, 133.2, 130.0, 128.1, 127.9, 127.0, 122.3, 
114.4, 113.2, 86.7, 86.2, 84.5, 72.7, 63.8, 55.7, 55.3, 40.3, 31.6, 27.9 ppm; HRMS 
(ESI): calcd for C41H40N4O8H [M+H]+ 717.29244 found 717.29166, and 
C41H40N4O8Na [M+Na]+ 739.27438 found 739.27257. 
Compound 43d: Flash chromatography (SiO2, EtOAc/acetone/Et3N 100:1:4 to 
100:5:4) gave 43d as a white foam (435 mg, 84%): TLC Rf = 0.71 (EtOAc/acetone 
10:6); 1H NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 8.17 (s, 1H), 7.39 – 7.15 (m, 14H), 
7.06 (m, 2H), 6.79 (d, J = 8.9 Hz, 4H), 6.49 (t, J = 6.5 Hz, 1H), 4.70 – 4.66 (m, 1H), 
4.16 (q, J = 4.6 Hz, 1H), 3.75 (s, 6H), 3.65 (t, J = 7.2 Hz, 2H), 3.49 (q, J = 7.0 Hz, 
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1H), 3.40 (t, J = 4.8 Hz, 2H), 3.24 (t, J = 7.4 Hz, 2H), 2.88 (dd, J = 6.6, 13.3 Hz, 
1H), 2.56 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ 170.9, 159.7, 158.2, 151.8, 
150.4, 149.8, 144.1, 142.1, 135.3, 135.3, 132.9, 129.7, 129.0, 127.7, 127.6, 126.6, 
125.4, 121.2, 112.9, 86.4, 85.9, 84.2, 72.3, 63.5, 55.0, 40.0, 31.3, 27.6 ppm; HRMS 
(ESI): calcd for C40H38N4O7H [M+H]+ 686.28188 found 687.28009. 
Compound 43e: Flash chromatography (SiO2, DCM/MeOH/Et3N 100:0:4 to 
100:3:4) gave 43e as a white foam (435 mg, 79%): TLC Rf = 0.77 (DCM/MeOH 
20:1); 1H NMR (400 MHz, CDCl3) δ 8.76 (s, 1H), 8.15 (s, 1H), 7.38 (d, J = 7.1 Hz, 
2H), 7.28 – 7.17 (m, 13H), 6.79 (d, J = 8.8 Hz, 4H), 6.49 (t, J = 6.4 Hz, 1H), 4.71 – 
4.67 (m, 1H), 4.15 (q, J = 5.2, Hz, 1H), 3.76 (s, 6H), 3.55 (t, J = 7.4 Hz, 2H), 3.41 
– 3.36 (m, 2H), 3.25 (t, J = 7.4 Hz, 2H), 3.11 (t, J = 7.1 Hz,  2H), 2.90 – 2.80 (m, 
3H), 2.57 – 2.42 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3) δ 197.8, 160.1, 158.6, 
152.2, 150.2, 144.4, 142.4, 135.6, 130.0, 128.6, 128.5, 128.1, 127.9, 127.0, 126.5, 
113.2, 86.7, 86.1, 84.5, 72.8, 63.8, 55.4, 41.2, 40.2, 36.0, 30.5, 29.9, 28.3 ppm; 
HRMS (ESI): calcd for C42H42N4O6SH [M+H]+ 731.29033 found 731.28609, and 
C42H42N4O6SNa [M+Na]+ 753.27227 found 753.26971.  
General procedure for converting 43a-43e to 1-5: To a solution of 43a (600 mg, 
0.94 mmol, 1.0 equiv.), 43b (500 mg, 0.75 mmol, 1.0 equiv.), 43c (400 mg, 0.56 
mmol, 1.0 equiv.), 43d (400 mg, 0.58 mmol, 1.0 equiv.), or 43e (400 mg, 0.54 
mmol, 1.0 equiv.) in anhydrous DCM (50 mL) was added diisopropylammonium 
tetrazolide (1.5 equiv.) under positive argon pressure and 2-cyanoethyl N,N,N',N'-
tetraisopropylphosphorodiamidite (1.5 equiv.) via a syringe at r.t. with rigorous 
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stirring. The reaction was allowed to proceed at r.t. for 2 h. Volatiles were removed 
under reduced pressure. The products were purified with flash chromatography to 
give 1-5, respectively.  
Compound 1: Flash chromatography (SiO2, hexanes/EtOAc/Et3N 50:10:2 to 
5:30:3) gave 1 as a white foam (695 mg, 88%): two diastereomers; TLC Rf = 0.57, 
0.53 (hexanes/EtOAc 4:3); 1H NMR (400 MHz, CDCl3) δ  8.77 (s, 1H), 8.19 and 
8.18 (s, 1H), 7.39 – 7.35 (m, 2H), 7.28 – 7.15 (m, 7H), 6.78 – 6.74 (m, 4H), 6.49 – 
6.45 (m, 1H), 4.80 – 4.72 (m, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.86 – 3.80 (m, 1H), 
3.76 – 3.75 (m, 6H), 3.67 – 3.57 (m, 4H), 3.52 (t, J = 7.5 Hz, 2H), 3.40-3.28 (m, 
3H), 2.98 – 2.92 (m, 2H), 2.62 (t, J = 6.3 Hz, 1H), 2.47 (t, J = 6.4 Hz, 1H), 1.22 – 
1.09 (m, 15H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.6, 160.5, 158.5, 152.2, 
144.5, 142.4, 135.6, 135,6, 133.2, 130.1, 130.0, 130.0, 128.1, 128.1, 127.8, 126.9, 
126.9, 113.1, 86.5, 84.6, 84.6, 86.5,84.6, 84.6, 63.6, 63.4, 60.6, 55.3, 55.3, 43.5, 
43.3, 39.5, 31.7, 28.0, 24.8, 24.7, 24.7, 24.7, 14.4 ppm; 31P NMR (162 MHz, CDCl3) 
δ 150.2, 150.0 ppm; HRMS (ESI): calcd for C45H55N6O8PH [M+H]+ 839.38972 
found 839.38853, and C45H55N6O8PNa [M+Na]+ 861.37162 found 861.36923. 
Compound 2: Flash chromatography (SiO2, hexanes/EtOAc/Et3N 50:10:2 to 
50:40:4) gave 2 as a white foam (mg 510 mg, 80%): two diastereomers; TLC Rf = 
0.45, 0.43 (hexanes/EtOAc 4:3); 1H NMR (400 MHz, CDCl3) δ 8.76 (s, 1H), 8.17 
(s, 1H), 7.37 – 7.34 (m, 2H), 7.29 – 7.14 (m, 7H), 6.77-6.74 (m, 4H), 6.49 (t, J = 
7.3 Hz, 1H), 4.71-4.76 (m, 1H), 4.31 – 4.27 (m, 1H), 4.23 – 4.19 (m, 2H), 3.88-3.78 
(m, 2H), 3.75 (s, 6H), 3.57 – 3.49 (m, 5H), 3.36 – 3.30 (m, 4H), 3.02 (t, J = 7.4 Hz, 
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2H), 2.93 – 2.87 (m, 1H), 2.75-2.71 (m, 1H), 2.61 (t, J = 6.3 Hz, 2H), 2.46 (t, J = 
6.4 Hz, 1H), 1.28 – 1.22 (m, 3H), 1.18 – 1.14 (m, 6H), 1.11-1.09 (m, 3H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 172.6, 160.4, 158.5, 152.1, 150.2, 144.5, 142.4, 135.6, 
135.6, 133.2, 130.0, 128.1, 128.1, 127.8, 126.9, 117.5, 113.1, 86.5, 85.9, 84.6, 
70.5, 63.7, 63.6, 59.1, 58.5, 58.3, 55.3, 43.5, 43.3, 39.5, 31.5, 27.9, 24.8, 24.7, 
24.6, 23.09, 20.58 ppm; 31P NMR (162 MHz, CDCl3) δ 150.2, 150.1 ppm; HRMS 
(ESI): calcd for C46H57N6O9PH [M+H]+ 869.40029 found 869.40006, and 
C46H57N6O9PNa [M+Na]+ 891.382223 found 891.37988. 
Compound 3: Flash chromatography (SiO2, hexanes/EtOAc/Et3N 50:10:2 to 
50:40:4) gave 3 as a white foam (415 mg, 81%): two diastereomers; TLC Rf = 0.46, 
0.44 (hexanes/EtOAc 4:3); 1H NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 8.21 and 
8.19 (s, 1H), 7.38 – 7.36 (m, 2H), 7.28 – 7.16 (m, 7H), 6.98 (d, J = 9.0 Hz, 2H), 
6.84 – 6.74 (m, 6H), 6.51 – 6.46 (m, 1H), 4.76 (s, 1H), 4.29 (s, 1H), 4.21 – 4.07 
(m, 2H), 3.84-3.79 (m, 1H), 3.76 (s, 6H), 3.66 – 3.54 (m, 4H), 3.40 – 3.29 (m, 2H), 
3.21 (t, J = 7.2 Hz, 2H), 2.95 – 2.88 (m, 1H), 2.77 – 2.56 (m, 4H), 2.47 (t, 6.36 Hz, 
1H), 1.28 – 1.24 (m, 3H), 1.21 – 1.14 (m, 6H), 1.12 (d, J = 6.7 Hz, 3H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 171.6, 160.0, 158.5, 157.1, 152.2, 144.5, 144.3, 142.5, 
135.7, 133.2, 130.0, 128.1, 127.8, 126.9, 122.3, 114.4, 113.2, 86.6, 84.7, 55.7, 
55.3, 43.5, 43.5, 43.4, 39.5, 31.6, 28.0, 24.8, 24.8, 24.7, 24.7, 23.2, 23.2, 23.1, 
23.1 ppm; 31P NMR (162 MHz, CDCl3) δ 150.2, 150.0 ppm; HRMS (ESI): calcd for 
C50H57N6O9PH [M+H]+ 917.40029 found 917.40014 and C50H57N6O9PNa [M+Na]+ 
939.38223 found 939.37995. 
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Compound 4: Flash chromatography (SiO2, hexanes/EtOAc/Et3N 50:10:2 to 
50:40:4) gave 4 as a white foam (420 mg, 81%): two diastereomers; TLC Rf = 0.50, 
0.47 (hexanes/EtOAc 4:3); 1H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H), 8.22 and 
8.20 (s, 1H), 7.38 – 7.35 (m, 2H), 7.33 – 7.12 (m, 10H), 7.06 (d, J = 8.0 Hz, 2H), 
6.77 (dd, J = 4.9, 8.5 Hz, 4H), 6.50 (m, 1H), 4.78 (m, 1H), 4.31 (m, 1H), 4.14 – 4.04 
(m, 1H), 3.83 (m, 1H), 3.74 (s, 3H), 7.35 (s, 3H), 3.65 (t, J = 6.6 Hz, 2H), 3.57 – 
3.29 (m, 4H), 3.24 (t, J = 7.2 Hz, 2H), 2.99 – 2.89 (m, 1H), 2.71-2.67 (m, Hz, 1H), 
2.59 (t, J = 6.3 Hz, 1H), 2.46 (t, J = 6.3 Hz, 1H), 1.25 (d, J = 6.5 Hz, 4H), 1.18 (s, 
6H), 1.11 (d, J = 6.8 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 171.2, 160.0, 
158.5, 152.2, 150.8, 150.2, 144.5, 142.5, 135.7, 133.2, 130.0, 129.3, 128.2, 128.1, 
127.8, 126.9, 125.7, 121.6, 117.4, 113.2, 86.6, 86.0, 84.7, 73.6, 63.6, 63.4, 58.6, 
58.4, 55.4, 55.3, 43.5, 43.4, 39.5, 31.6, 27.9, 24.70, 23.1, 20.4 ppm; 31P NMR (162 
MHz, CDCl3) δ 150.1, 150.0 ppm;  HRMS (ESI): calcd for C49H55N6O8PH [M+H]+ 
887.38972 found 887.38934, and C49H55N6O8PNa [M+Na]+ 909.337167 found 
909.36998. 
Compound 5: Flash chromatography (SiO2, hexanes/EtOAc/Et3N 50:0:2 to 
50:20:3) gave 2.5e as a white foam (400 mg, 79%): two diastereomers; TLC Rf = 
0.63, 0.58 (hexanes/EtOAc 2:1); 1H NMR (400 MHz, CDCl3) δ 8.77 and 8.76 (s, 
1H), 8.20 and 8.18 (s, 1H), 7.38 – 7.35 (m, 2H), 7.32 – 7.09 (m, 12H), 6.78-7.74 
(m, 4H), 6.48 – 6.43 (m, 1H), 4.32- 4.27 (m, 1H), 4.16 – 4.09 (m, 1H), 3.86 – 3.80 
(m, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 3.60 – 3.57 (m, 1H), 3.58 (t, J = 7.2 Hz, 2H), 
3.48 – 3.40 (m, 2H), 3.39 – 3.30 (m, 2H), 3.24 (t, J = 7.3 Hz, 2H), 3.11 (t, J = 7.2 
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Hz, 2H), 2.95-2.88 (m, 1H), 2.85 (t, J = 8.2 Hz, 2H), 2.74 (t, J = 6.2 Hz, 1H), 2.61 
(t, J = 7.9 Hz, 1H), 2.46 (t, J = 6.4 Hz, 1H), 1.24-1.20 (m, 4H), 1.19-1.17 (m, 6H), 
1.15-1.10 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 197.8, 160.0, 158.5, 152.2, 
150.2, 144.5, 142.5, 140.0, 135.7, 133.2, 130.1, 130.0, 130.0, 128.6, 128.5, 128.2, 
128.1, 127.8, 126.9, 126.4, 113.2, 86.6, 84.7, 63.6, 63.4, 55.4, 55.3, 58.6, 58.4, 
45.8, 45.7, 43.5, 43.4, 41.2, 39.5, 36.1, 30.5, 29.9, 28.3, 24.8, 24.7, 23.3, 22.4, 
20.7, 20.5 ppm; 31P NMR (162 MHz, CDCl3) δ 150.1, 150.0 ppm; HRMS (ESI): 
calcd for C51H59N6O7PSH [M+H]+ 931.39818 found 931.39691. 
2.4 Synthesis of chloropurine monomer 6 
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Scheme 2.4 Synthesis of chloropurine monomer 6 
While we were studying the cross-linking properties of oligodeoxynucleotides we 
came across the applications of chloropurines. Chloropurines shown to have 
cytotoxic,[8-12] antiviral,[13-15] antitumor[8, 10, 11, 16] and antioxidant[9, 17] properties. 
Chemical synthesis of chloropurines is quite possible[10, 17, 18] but their incorporation 
into oligonucleotide is complicated by ammonia work-up just like our sensitive 
esters. Their applications compel us to synthesize chloropurine monomer 6. 
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Another reason to extend our synthesis is to check the applicability of Dmoc 
technology in making of oligonucleotides having chloropurines in them. We had 
already synthesized a compound 36 to make monomers 1-5. Taking advantage of 
availability of the starting material we gave the way to our curiosity and synthesized 
it as shown in the Scheme 2.4. 
Compound 59: In an ice-cold solution of 36 (600 mg, 1.2 mmol, 1.0 equiv) in 20 
mL anhydrous THF under argon, slowly added 1.0 M tetrabutylammonium fluoride 
solution in THF (3.0 mL, 3.0 mmol, 2.5 equiv). The reaction mixture was stirred at 
0 ºC for 2.5 h. Solvent was evaporated in vacuo, residue was purified by flash 
chromatography (SiO2, DCM/MeOH 100/2 to 100/7) to get compound 59 as a light-
yellow oil (310 mg, 95%). TLC Rf = 0.44 (DCM/ MeOH 10/1); 1H NMR (400 MHz, 
DMSO) δ 8.88 (s, 1H), 8.64 (s, 1H), 6.50 (t, J = 6.6 Hz, 1H ), 4.5 (p, J = 2.84, 2.92, 
5.76 Hz, 1H), 3.97 (q, J = 3.3 Hz, 1H), 3.70 (dd, J = 3.6, 11.8 Hz, 1H), 3.62 (dd, J 
= 3.5, 11.9 Hz, 1H), 2.68 (m, 1H), 2.42 (m, 1H) ppm; 13C (100 MHz, DMSO) δ 
150.7, 150.7, 149.2, 144.7, 131.2, 87.9, 84.3, 70.3, 70.2, 61.2, 61.1, 40.2 ppm; 
HRMS (negative ACPI): Calcd For C10H11ClN4O3 + e  [M+e] 270.05197 found 
270.05329 and For C10H11ClN4O5 +e  [M+O2+e] 302.04179 found 302.04273. 
Compound 60: Compound 59 (300 mg, 1.11 mmol, 1.0 equiv) was dissolved in 
15 mL freshly distilled anhydrous pyridine under argon and 4,4-dimethoxytrityl 
chloride (414 mg, 1.22 mmol, 1.1 equiv) was added with rigorous stirring at room 
temperature. Reaction mixture was stirred at r.t. for 8 h, solvent was removed by 
evaporation. The residue was purified by flash chromatography (SiO2, 
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DCM/MeOH/Et3N 10/0/4% to 10/3/4%) to get 60 as a yellow foam (478 mg, 75%). 
TLC Rf = 0.71 (DCM/MeOH 10/0.6); 1H NMR (400 MHz, CDCl3) δ 8.64 (s, 1H), 
8.25 (s, 1H), 7.37 – 7.35 (m, 2H), 7.27 – 7.17 (m, 7H), 6.79 – 6.76 (m, 4H), 6.48 
(t, J = 6.5 Hz, 1H), 4.71 – 4.69 (m, 1H), 4.18 (q, J = 4.6 Hz, 1H), 3.77 (s, 6H), 3.49 
– 3.34 (m, 3H), 2.89 – 2.82 (m, 1H), 2.60 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3) 
δ 158.6, 151.9, 151.1, 144.3, 143.7, 135.5, 135.5, 130.0, 130.0, 128.0, 128.0, 
127.1, 113.3, 86.8, 86.4, 85.0, 72.7, 63.7, 55.4, 40.5 ppm; HRMS (ESI): Calcd For 
C31H29ClN4O5Na+ [M+Na+] 595.17241 found 595.17133. 
Compound 6: In a reaction flask at r.t. 60 (450 mg, 0.79 mmol, 1.0 equiv) was 
dissolved in 50 mL anhydrous DCM. To this solution added diisopropylammonium 
tetrazolide (208 mg, 1.19 mmol, 1.5 equiv) followed by the addition of 2-cyanoethyl 
N,N,N',N'-tetraisopropylphosphorodiamidite (378 µL, 1.19 mmol, 1.5 equiv) via 
syringe with rigorous stirring. Reaction mixture was stirred at r.t. for 2 h. Solvent 
was evaporated and the residue was purified by flash chromatography (SiO2, 
Hexanes/EtOAc/Et3N 5/1/4% to 5/4/4%) to get 6 as a white foam (510 mg, 84%), 
TLC for two diastereomers Rf = 0.55 and 0.51; 1H NMR (400 MHz, CDCl3) δ 8.67 
(s, 1H), 8.32 (two diastereomeric s, 1H), 7.39-7.36 (m, 2H), 7.29 – 7.19 (m, 7H), 
6.80 – 6.76 (m, 4H), 6.50-6.47 (m, 1H), 4.78 – 4.77 (m, 1H), 4.35– 4.33 (m, 1H), 
3.89 – 3.84 (m, 1H), 3.79 – 3.78 (m, 6H), 3.66 – 3.58 (m, 2H), 3.34 (dd, J = 10.2, 
4.6 Hz, 2H), 2.96 – 2.88 (m, 2H), 2.69-2.65 (m, 1H), 2.64 (t, J = 6.3 Hz, 1H), 2.49 
(t, J = 6.4 Hz, 1H), 1.21-1.18 (m, 9H), 1.16 – 1.13 (m, 3H) ppm; 13C NMR (100 
MHz, CDCl3) δ 158.5, 151.8, 144.4, 143.8, 135.6, 135.5, 130.1, 130.0, 128.1, 
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127.9, 127.0, 113.2, 86.7, 86.4, 85.2, 63.3, 58.6, 55.3, 43.5, 43.4, 39.8, 24.8, 20.5 
ppm; 31P NMR (162 MHz, CDCl3) δ 150.2, 150.1 ppm; HRMS (ESI): Calcd For 
C40H46ClN6O6PNa+ [M+Na+] 795.28027 found 795.27901 and For 
C40H46ClN6O6PH+Na+ [M+ H+Na+] 796.28809 found 796.28147. 
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3 Oligodeoxynucleotide Synthesis 
3.1 Introduction 
As discussed in Chapter 2, nucleobases 1-5, Dmoc phosphoramidites 7-9 and 
Dmoc linker 10 were synthesized and characterized. With these materials we were 
ready for the synthesis of oligonucleotides using Dmoc technology. The synthesis 
was accomplished over automated oligonucleotide synthesizer MerMade-6. No 
strong base was used for post synthesis work-up. Instead, post-synthesis work-up 
was conducted under nearly neutral conditions. Total of 16 modified 
oligonucleotides were synthesized. Also, five standard ODNs were made in order 
to use them as a natural complementary strand to the modified ODNs. This 
Chapter discusses the synthesis and work-up of ODNs in detail. 
3.2 Results and discussion 
Oligodeoxynucleotide synthesis was carried out using solid phase chemistry.[1] In 
general the ODN synthesis was carried out as follows (Scheme 3.1);[2] A linker 10 
was a standard support with a nucleobase DMTr-dT already installed on it. The 
ODN synthetic cycle started with detritylation of 10. The DMTr was removed by 
using acidic conditions to give a product 61 with unprotected alcohol at the 5' end. 
 The next step was coupling of 61 with a specific nucleobase 62. The nucleobase 
62 was different for every cycle and was decided based on the ODN sequence 
under synthesis. The first coupling gave a dimer 63, while subsequent couplings 
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resulted into trimer, tetramer etc. and finally the 20 mer ODN. The efficiency of 
coupling was assumed to be less than 100% as real-time analysis at this stage is 
unreasonable. Less than 100% coupling efficiency means there was some 
unreacted 61 in the synthesis column. This unreacted 61 generates the failure 
sequence. The failure sequence needed to be terminated to avoid the formation of 
complex ODN mixture at the end of the ODN synthesis. The capping of failure 
sequence was carried out during every synthesis cycle immediately after coupling 
step to give a process inert 64. In the last step trivalent phosphorus on the growing 
chain was converted to pentavalent phosphorus. For that oxidation was carried out 
using iodine to give 65. With the oxidation the first ODN synthesis cycle completed 
and an attachment of a nucleobase was achieved. The cycle was repeated to give 
an ODN of desired length. In our case all ODNs were 20 nucleobase long and all 
were starting with thymine at the 3' end as our solid support has dT already 
installed on it. 
Total of 16 modified ODN strands were synthesized using one modified monomer 
in each of them. All sequences were 20 nucleotides long and selected from DNA-
polymerase template. Synthesis was arranged according to their sensitivity; 
starting from a less sensitive to end with the most sensitive. The most stable 
modified monomer 1 was used first to make ODNs, followed by 2 and continued 
to monomer 5 in the order. 
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Scheme 3.1 Oligonucleotide synthesis cycle by Dmoc technology 
Two 20 mer deoxyoligonucleotide strands using modified monomer 1 were 
synthesized. Strand-1 was synthesized with modified monomer 1 at 10th position 
from 5' end while it was at the 1st position Strand-2 from the 5' end (Figure 3.1). 
This monomer was most stable of all synthesized monomers for the purpose. and 
the ODN synthesis was expected to be less troublesome. The trityl graph was 
excellent for every cycle and was an indication of a good ODN synthesis. Though 
trityl graph may be misleading sometime but it gives accurate information for the 
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synthesis of shorter oligonucleotides like the ones we targeted. So, for time being 
we decided to rely on it for the success of an ODN synthesis. Only two ODN 
strands were synthesized using monomer 1. 
 
Figure 3.1 Sequences of the ODN strands with monomer 1  
ODN synthesis by using modified monomer 2 was carried out next. Four ODN 
strands were synthesized with one modified monomer 2 in each of them. In 
Strand-3 it was placed at 9th position from 5' end while placed at 1st, 6th, and 19th 
position for Strand 4, 5, and 6, respectively (Figure 3.2). More ODN strands for 
this monomer were synthesized considering its sensitivity and likely work-up 
related problems. Another reason for making more strands with higher sensitivity 
monomers was their reactivity towards the nucleophiles. The chances of cross-
linking of ODN strands with monomers 2-5 were greater as they were having better 
leaving group than the monomer 1. This made us plan more ODN strands using 
monomers 2-5. 
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Figure 3.2 Sequences of the ODN strands with monomer 2  
Monomer 3 with methoxyphenyl ester was expected to be more sensitive to the 
acidic conditions employed during the ODN synthesis. four ODN strands (Figure 
3.3) using this monomer were synthesized. All preparations were double checked 
carefully before the synthesis. The Strand-7 8, 9, and 10 were synthesized with 3 
at 8th, 1st, 9th and 1st positions, respectively from 5' end (Figure 3.3). The trityl graph 
was normal for all ODNs and for all cycles in each one of them. As it was one of 
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the very sensitive monomers, it was difficult to say anything about the success of 
ODN synthesis. 
 
Figure 3.3 Sequences of the ODN strands with monomer 3 
We then moved on to the most sensitive monomers in the series we synthesized, 
monomer 4. Position of the modified monomer kept closer to 5' end to minimize its 
exposure to the acidic conditions. The results for ODN syntheses were normal. We 
synthesized three ODN strands using this monomer; Strands 11, 12 and 13 with 
monomer 4 at 1st, 5th and 1st positions (Figure 3.4), respectively from the 5' end.  
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Figure 3.4 Sequences of the ODN strands with monomer 4 
All ODN syntheses using monomers 1-4 were excellent, at least on trityl monitor. 
So, we moved on to the monomer 5. The sensitivity of monomer 5 was expected 
to be like monomer 3 and 4. The ODN Strands 14, 15, and 16 were synthesized 
with monomer 5 at 1st, 12th, and 10th positions (Figure 3.5), respectively form 5' 
end. 
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Figure 3.5 Sequences of the ODN strands with monomer 5 
The synthesis of ODNs with modified monomers at different positions and 
synthesis of multiple strands using each monomer was necessary in order tackle 
the challenges we were about to face during ODN work-up and purification. The 
ODN synthesis of even a very sensitive monomer such as the one with phenyl 
ester was excellent on trityl monitor but we were little suspicious about its survival 
during the work-up. So, we kept multiple options ready to explore all possible ways 
in the event of any such problems during work-up and purification. 
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Scheme 3.2 Post synthesis work-up of ODNs 
 After their synthesis the ODN strands were worked-up to get them cleaved from 
CPG and to remove Dmoc protections (Scheme 3.2). ODN strands with sensitive 
ester groups on 66 were treated with DBU to remove cyanoethyl group followed 
by oxidation of sulfurs on Dmoc protections using sodium periodate to give 67. In 
the next step β-elimination by aniline gave final ODNs 68 in their crude forms. 
These crude ODNs were purified by reverse phase high performance liquid 
chromatography (RP-HPLC) to get pure ODN strands. Purification by RP-HPLC 
followed by MALDI-Tof mass determination have shown very good results for 
ODNs containing modified nucleobases 1 (Figures 3.6, 3.7 and 3.8 shown for ODN 
Strand-1), nucleobase 2 (Figures 3.9, 3.10 and 3.11 shown for ODN Strand-5) 
and nucleobase 5 (Figure 3.12, 3.13 and 3.14 shown for ODN Strand-14).  
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Figure 3.6 HPLC profile for ODN Strand-1 (crude) 
 
 
Figure 3.7 HPLC profile for ODN Strand-1 (pure) 
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Figure 3.8 MALDI-Tof spectrum ODN Strand-1  
 
 
Figure 3.9 HPLC profile for ODN Strand-5 (crude) 
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Figure 3.10 HPLC profile for ODN Strand-5 (pure) 
 
 
Figure 3.11 MALDI-Tof spectrum ODN Strand-5 
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Figure 3.12 HPLC profile for ODN Strand-14 (crude) 
 
 
 
Figure 3.13 HPLC profile for ODN Strand-14 (pure) 
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Figure 3.14 MALDI-Tof spectrum ODN Strand-14 
But there was a problem with the work-up of ODNs with modified monomers 4 and 
5. We used aniline for β-elimination during the work-up of ODNs according to the 
Dmoc technology protocol. But, when ODNs with methoxyphenyl ester (a group 
on monomer 4) and phenyl ester (a group on monomer 5) were worked-up with 
this protocol, aniline was found to be replacing methoxyphenyl and phenyl groups 
buy nucleophilic substitution reaction.  
When ODN 69 and ODN 70 containing methoxyphenyl and phenyl groups, 
respectively were treated with aniline. The substitution was occurring instead of β-
elimination to give substituted product 71 (Scheme 3.3). The substitution was 
verified by purification of Strand-7 ( a methoxyphenyl strand) and Strand-12 (a 
phenyl strand) using RP-HPLC and by MALDI-Tof analysis (Figures 3.15, 3.16, 
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3.17 and 3.18). The substituted and non-substituted products were observed 
almost in 1:1 ratio. 
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Scheme 3.3 Substitution by an aniline 
 
  
Figure 3.15 HPLC profile of ODN Strand-7 after aniline work-up 
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Figure 3.16 MALDI-Tof spectra of ODN Strand-7 HPLC fractions after aniline 
work-up 
  
Figure 3.17 HPLC profile of ODN Strand-12 after aniline work-up 
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Figure 3.18 MALDI-Tof spectra of ODN Strand-12 HPLC fractions after aniline 
work-up 
The substitution instead of β-elimination was a big problem on the way to the 
development of potential oligonucleotide cross-linking agents using modified 
monomers 4 and 5. To address this problem, we replaced 3% aniline suspension 
in water with 0.5% 4-aminobenzyl alcohol and carried the deprotection and 
cleavage (Scheme 3.4) under otherwise identical conditions. The lower 
nucleophilicity of 4-aminobenzyl alcohol was expected to minimize the substitution 
of sensitive methoxyphenyl and phenyl esters. Indeed, the results were much 
better. The analytical data for Strand-7 (Figure 3.19, 3.20 and 3.21) and for 
Strand-12 (Figure 3.22, 3.23 and 3.24). When the interval was long, more 
hydrolysis products were observed, but the yields of target ODNs were high 
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without any substituted ODNs. 
 
Scheme 3.4 β-Elimination using 4-aminobenzyl alcohol 
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Figure 3.19 HPLC profile of ODN Strand-7 (crude) after 4-aminobnzyl alcohol 
work-up 
 
 
Figure 3.20 HPLC profile of ODN Strand-7 (pure) after 4-aminobnzyl alcohol 
work-up 
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Figure 3.21 MALDI-Tof spectrum of ODN Strand-7 
 
 
Figure 3.22 HPLC profile of ODN Strand-12 (crude) after 4-aminobnzyl alcohol 
work-up 
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Figure 3.23 HPLC profile of ODN Strand-12 (pure) after 4-aminobnzyl alcohol 
work-up 
 
 
Figure 3.24 MALDI-Tof spectrum of ODN Strand-12 
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aminobenzyl alcohol was used. All ODNs were then purified by RP-HPLC followed 
by a characterization using MALDI-Tof. The yields for ODN strands were 
calculated using UV-Visible absorbance at 260 nm.  
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Figure 3.25 UV-Visible scan spectrum for Strand-1 
For optical density measurement UV-Visible scan spectrum was obtained for each 
modified ODN like the one shown in Figure 3.25 for ODN Strand-1. The 
absorbance at 260 nm was taken as a maximum absorbance. 
The sample calculations for Strand-1 are shown as follows; 
Molar mass of the ODN Strand-1 was obtained using an online tool developed by 
Northwestern university[3] as 6125 da (or g/mol). Synthesis of ODNs calculated for 
20 mg of solid support 10 to be 0.52 µmol = 0.52 ×10-6 mol. Molar Extinction 
Coefficient (ɛ) = 190300.00 liter.mol-1.cm-1 calculated by considering modified 
monomer equivalent to adenine. Length of the cell was (l) = 1 cm. Absorbance (A) 
for ODN Strand-1 at 260 nm = 0.1900 (Figure 3.25). Dilution factor = 10 (1/10th of 
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product worked-up) × 10 (1/10th of worked-up product was purified) × 2.5 (the 
purified product was diluted to 2.5 mL DI water) = 250 
 
Table 3.1 Yields for modified ODN strands 
Optical density (0.1900 × 250)    = 47.5 
Expected yield (6125 ×0.52 ×10-6)   = 3.1850 mg 
Concentration (c = A/ ɛ.l)      = 9.98 × 10-7 M 
The number of moles in 1.0 ml sample solution  = 9.98 × 10-10 mol 
Yield (6125 g/mol × 9.98 × 10-10 mol × 250)   = 1.5282 mg 
Percent Yield (1.5282/3.1850 × 100)   = 48.98%  
The OD and yield calculations were performed for all remaining modified ODN 
strands using same method described above (Table 3.1). The highest yield was 
ODN 
Strands 
(ɛ) 
Expected 
Yield 
A at 
260 nm 
OD c Yield 
% 
Yield 
2 183500.00 3.1725 0.1905 47.63 10.38 × 10-7 1.5832 49.90 
3 176000.00 3.1944 0.2859 71.48 16.24 × 10-7 2.4941 78.08 
4 188600.00 3.2271 0.2108 52.70 11.18 × 10-7 1.7346 53.75 
5 193600.00 3.1923 0.3257 81.43 16.82 × 10-7 2.5814 80.86 
6 190300.00 3.2006 0.2405 60.13 12.64 × 10-7 1.9450 60.77 
7 203900.00 3.2188 0.2160 54.00 10.59 × 10-7 1.6388 50.91 
8 194300.00 3.2063 0.3225 80.63 16.60 × 10-7 2.5589 79.81 
9 203000.00 3.2396 0.1833 45.83 9.03 × 10-7 1.4064 43.41 
10 195100.00 3.2219 0.1476 36.90 7.57 × 10-7 1.1716 36.39 
11 212300.00 3.2594 0.1357 33.93 6.39 × 10-7 1.0013 30.72 
12 192900.00 3.2219 0.1443 36.08 7.48 × 10-7 1.1587 35.96 
13 186300.00 3.2126 0.1469 36.73 7.89 × 10-7 1.2179 37.91 
14 195300.00 3.1652 0.2169 54.23 11.11 × 10-7 1.6907 53.41 
15 199200.00 3.1517 0.2258 56.45 11.34× 10-7 1.7176 54.50 
16 206100.00 3.1850 0.1970 49.25 9.56 × 10-7 1.4639 45.96 
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found for ODN Strand-5 at 80.86% and lowest yield was reported for ODN Strand-
8 at 30.72%. 
For cross-linking studies, we needed complementary unmodified ODNs which 
were synthesized by using standard phosphoramidites and standard ODN 
synthesis cycle as well as work-up. We synthesized five unmodified 20 mer ODN 
strands complementary to modified ODN strands 1, 3, 7, 12 and 15. Modified ODN 
strands were selected based on the position of modified monomer. In all selected 
modified strands, the position of respective monomer was somewhere in the 
middle of the ODN. The middle position of the modified monomer in an ODN was 
expected to be better for the formation of double helical configuration with 
complementary ODN strand. Both ends with natural nucleobases could interact 
with complementary ODN strand to facilitate double helix configuration holding 
modified monomer tightly to one place.  
3.3 Experimental section 
3.3.1 General Experimental 
ODNs were synthesized on MerMade 6 solid phase oligo synthesizer. Solvents 
and reagents were bought from various commercial sources and used as they 
were. For ODN synthesis 0.1 M solutions of all phosphoramidite (including 
modified) were prepared in anhydrous acetonitrile. For ODN Synthesis volumes of 
phosphoramidite solutions were calculated according to the amount to be delivered 
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to avoid wastage. Vacuum calibration of MerMade 6 was performed before each 
new batch of the synthesis using Dmoc linker 10 and standard phosphoramidite 
solutions to ensure exact delivery of reagents and for maximum exposure of linker 
10 to the reagents. Standard Cap-A was replaced by phenoxyacetic anhydride for 
the synthesis of modified ODNs. RP-HPLC was performed on a JASCO LC-
2000Plus System: pump, PU-2089Plus Quaternary Gradient; detector UV-
2075Plus. For RP-HPLC a C-18 reverse phase analytical column (5μm diameter, 
100 Å, 250 × 3.20 mm) was used. RP-HPLC mobile phase: Solvent A: 0.1 M 
triethylammonium acetate, 5% aqueous acetonitrile. Solvent B: 90% aqueous 
acetonitrile. RP-HPLC profiles were generated by detection of absorbance of ODN 
at 260 nm using the linear gradient solvent system: solvent B (0%-45%) in Solvent 
A over 60 min followed by Solvent B (45%-100%) in Solvent A over 20 min at a 
flow rate of 1.0 mL/min. Products were analyzed by Bruker Microflex LRF MALDI-
Tof to confirm the synthesis of desired ODN. UV-Visible scan spectrum was 
recorded for each purified ODN using Perkin Elmer Lamda 35 UV-Visible 
spectrophotometer. 
3.3.2 Synthesis of oligodeoxynucleotides 
An ODN synthesis was carried out using standard ODN synthesis cycle (Scheme 
3.1) The slight changes were incorporated to use Dmoc technology efficiently. 
Other than the Dmoc protected phosphoramidites 7-9 and Dmoc linker 10, 
commercially available dT-phosphoramidite was used. Dmoc technology requires 
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same reagents so all other reagents were obtained from commercial sources and 
used as they were. 20 mg of Dmoc linker 10 with a loading of 26 µmol/gm was 
taken in the synthesis column and column was packed with suitable frits from both 
ends. The synthesis of ODN was expected to be 0.52 µmol. The ODN synthesis 
cycle involved sequential detritylation, coupling, capping and oxidation. Each step 
was programmed correctly to ensure the sequence of events throughout the ODN 
synthesis cycle. 
3.3.2.1 Detritylation 
The ODN synthesis cycle started with the detritylation of a base already present 
on a solid support 10. Detritylation was carried out using 3% difluoro acetic acid in 
dichloromethane. 180 µL of detritylating agent was delivered to the ODN synthesis 
column and vacuum pulse for 30 ms was applied immediately to pull the reagent 
down to the bottom. Wait time for the step was adjusted to 45 s before another 
vacuum pulse. Wait time after second vacuum pulse was same i.e. 45 s. At the 
end of 90 second reagent present in the column was drained off and fresh 
detritylating agent was delivered one more time and all previous steps were 
repeated to ensure complete detritylation. After the completion of detritylation 
product was washed thoroughly using anhydrous acetonitrile (180 µL× .3 times). 
After washing the cycle was allowed to proceeded to the coupling step.  
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3.3.2.2 Coupling 
During this step 90 µL solution of a desired phosphoramidite (0.1 M in acetonitrile) 
was delivered to the column with 90 µL of an activator 5-ethythio-1H-tetrazole (0.25 
M in acetonitrile). A vacuum pulse of 35 ms was applied. After 60 s of wait time 
another vacuum pulse was applied. After second wait time for 60 s, the reagent 
was drained off and fresh phosphoramidite solution was delivered. To maximize 
the yield, coupling was carried out three times by repeating the steps above. At the 
end solid support was washed thoroughly using anhydrous acetonitrile (180 µL× 
.3 times). Capping was the next step to complete.  
3.3.2.3 Capping 
Capping was performed by delivering 90 µL of Cap-A (THF: phenoxyacetic acid: 
2,6-lutidine 80:10:10) and 90 µL of Cap-B (16% v/v solution of 1-methyl-
immidazole in THF). Two vacuum pulses for 30 s each and two wait times of 45 s 
each were applied. Capping was carried out only once. Washing by anhydrous 
acetonitrile (180 µL× .3 times) was carried out at the end before moving to next 
step. 
3.3.2.4 Oxidation 
180 µL of oxidizing solution (0.02 M iodine in v/v 1/1/1 THF/pyridine/H2O) was 
delivered to the column. Two vacuum pulses for 30 s each and two wait times of 
45 s each were applied. Oxidation was carried out only once. At the end solid 
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support was washed thoroughly using anhydrous acetonitrile (180 µL× .3 times). 
3.3.2.5 Next cycle 
After the first synthesis cycle dimer was a desired ODN strand and ready for the 
next round of synthetic cycle. The synthesis cycle was repeated another 18 times 
by delivering appropriate phosphoramidite solution during each cycle to get 20 mer 
ODNs. Each 20 mer ODN was synthesized using one modified nucleobase from 
modified nucleobases 1-5.  
3.3.3 Post synthesis ODN work-up 
Unmodified complementary ODN strands were worked-up by treating CPG after 
synthesis with ammonium hydroxide solution at 55 °C for 8 hours. They were 
purified by RP-HPLC using preparative column to get enough amount to conduct 
cross-linking experiments. Modified ODNs were worked-up by Dmoc protocol. 
3.3.3.1 Work-up using Dmoc technology protocol 
Following procedure for the ODN work-up was adopted[2] to keep sensitive esters 
intact. 
Taken 1/10th (2.2 mg) of ODN on CPG after ODN synthesis in 2.0 mL Eppendorf 
tube. DBU (10% in an anhydrous acetonitrile) 1.0 mL was added to it, tube was 
capped, sealed, vortexed gently, and rotated for 15 minutes. The tube with sample 
was centrifuged at 2.5 × 103 rpm for 30 seconds and DBU solution was removed 
 79   
carefully by micropipette. To wash residual DBU from ODN sample, 200 µL 
acetonitrile was added in to the tube, tube was vortexed gently, centrifuged at 2.5 
× 103 for 30 seconds and supernatant was removed carefully. The washing was 
repeated twice to ensure no more DBU was left in the ODN sample tube. To oxidize 
sulfur protecting groups on DNA as well as sulfurs on the linker, 1.0 mL, 0.4M 
NaIO4 solution was added to the tube. Tube was capped, sealed, vortexed gently, 
and rotated for 3 h. NaIO4 solution in the sample tube was changed with the fresh 
1.0 mL, 0.4M NaIO4 solution every 60-65 minutes. The tube with ODN and NaIO4 
solution from last step was centrifuged at 2.5 × 103 rpm for 30 seconds and NaIO4 
solution was removed carefully by micropipette. Washing was carried out by 
following the same procedure used to wash DBU except DI water (200 µL × 3) was 
used for washing instead of acetonitrile. Cleavage and deprotection of DNA was 
carried out in an aniline suspension/solution (3 % in water). 1.0 mL aniline solution 
was added into the sample tube, tube was capped, sealed, vortexed gently, and 
rotated for 1 hour. The tube with sample was centrifuged at 5.0 × 103 rpm for 3 
minutes and supernatant was removed carefully and collected in a different 2.0 mL 
Eppendorf tube. DI water was added to the ODN sample tube, vortexed gently and 
centrifuged at 5.0 × 103 rpm for 3 minutes. Supernatants were combined in the 
Eppendorf tube.  Obtained about 1.4 mL of the DNA solution. Solvent (mostly water 
and very little aniline) was evaporated over high vacuum and volume was reduced 
to approximately 50 µL.  To this residue 1-Butanol (500 µL) was added, the tube 
was capped, vortexed strongly for 1 minute, and the solution was centrifuged at 
14.5 × 103 rpm for 15 minutes. Supernatant was removed by micropipette 
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completely to get invisible or barely visible precipitate with crude DNA.  The 
precipitate was dissolved in 200 µL DI water, vortexed and centrifuged at 5.0 × 103 
rpm for 2 minutes. 20 µL crude ODN sample was injected to HPLC by sample 
syringe and purified it to get pure ODN. Rest of the 180 µL of crude sample was 
purified by using a preparative column by RP-HPLC to obtain enough amount of 
ODN for cross-linking experiments. 
3.3.3.2 Modification of Dmoc ODN work-up protocol  
An aniline was replaced by 0.5% 4-amonobenzyl alcohol solution for ODNs 
containing monomers 3 and 4 while rest of the procedure from Dmoc work-up 
protocol kept same. Except phenyl esters, all other monomers were cleaved and 
deprotected by using an aniline suspension/solution (3 % in water) with the 
procedure described earlier. After each successful work-up ODNs were purified by 
RP-HPLC followed by MALDI-Tof analysis and optical density measurements by 
UV-Visible spectroscopy. 
3.3.4 MALDI-Tof mass analysis 
3.3.4.1 Matrix preparation 
3-HPA (3- hydroxy picolinic acid) was selected as a matrix for ODNs and Bruker 
Daltonics protocol[4] for matrix preparation was used with appropriate adjustments 
as follows; 
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Prepared 1 mL 0.1% solution of TFA (trifluoroacetic acid) in water. 500 µL of this 
0.1% TFA solution was taken in an Eppendorf tube and to it added 500 µL 
acetonitrile. To it added 10 mg of diammonium hydrogen citrate and dissolved it 
completely by vortexing. This solution is named as TA50 by Bruker Daltonics. 500 
µL of TA50 was taken in another Eppendorf tube and approximately 5 mg of 3-
HPA was added to it. The mixture was vortexed strongly for about 1 minute to 
dissolve all 3-HPA. Another batch of about same amount of 3-HPA was added to 
previously obtained solution and vortexed to dissolve it. The addition of 3-HPA and 
vortexing was continued till some of 3-HPA was found insoluble. The mixture was 
sonicated for 5 minutes to dissolve maximum of 3-HPA. This saturated mixture 
was centrifuged at 5.0 × 103 rpm for 3 minutes. Supernatant was removed and 
clear solution was used as a matrix solution. 
3.3.4.2 Sample preparation 
All ODN samples modified as well as unmodified were purified and then the pure 
ODNs were repurified again by RP-HPLC to ensure maximum purity. Pure ODNs 
were collected manually in Eppendorf tubes. 5 µL of the repurified sample from 
about 2 mL of total volume collected during repurification was taken separately for 
MALDI-Tof mass analysis. This 5 µL of pure ODN sample was dried over Centrivac 
and then dissolved in 50 µL of DI water. This solution served as an ODN sample 
for MALDI-Tof mass analysis. 
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0.5 µL of matrix was applied on a ground steel Maldi Target and let it dry for 30 
minutes. On this dried matrix 0.5 µL of ODN sample was applied and allowed to 
dry it for another 30 minutes. Drying was extended up to 2 hours whenever 
necessary. 
3.3.4.3 Preparation of calibration standards 
Laboratory synthesized standard DNAs, purified and characterized accurately 
were used as standards for calibration of MALDI-Tof. ODN selected for calibration 
was always within the mass range ± 100 da of the sample ODN. The standards 
were prepared using the same procedure used for sample preparation. 
3.3.4.4 Data acquisition 
The MALDI data were acquired in negative mode. First the mass for a standard 
calibrant was recorded and the equipment was calibrated to this exact mass. 
Calibration was checked by acquiring data for the standard calibrant at least twice 
after calibration. After calibration was found correct the data for sample ODNs were 
recorded. The recorded mass for all modified ODNs and unmodified 
complementary ODNs was found within acceptable range (± 0.01%). 
3.3.5 UV-Visible measurements  
For optical density measurement and yield calculations UV-Visible scan spectrum 
was obtained for each modified ODN. 
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The ODN sample was purified and then repurified by RP-HPLC as described 
earlier. This repurified ODN sample was then dried over Centrivac. The completely 
dried ODN sample was the dissolved in 2.5 mL of DI water. The UV-Visible 
absorbance scan spectrum was recorded over 400 nm – 200 nm range. The 
absorbance at 260 nm was taken as a maximum absorbance.  
3.4 Synthesis of ODNs using monomer 6 
As discussed earlier in last chapter another modified monomer 6 was synthesized 
to check the feasibility of Dmoc technology. Using same modified ODN synthesis 
cycle used for making ODN Strands 1-16, synthesis of two ODN Strands 17 and 
18 (Figure 3.26) using modified monomer 6 was accomplished. The ODN work-up 
with the use of aniline as a scavenger worked great. Purification of ODNs was 
carried out using RP-HPLC by following the same procedure to get pure ODNs 
(Figures 3.27 and 3.28). MALDI-Tof mass analysis confirmed the successful 
incorporation of modified monomer 6 into ODN (Figure 3.29). 
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Figure 3.26 Sequences of the ODN strands with monomer 6 
 
 
Figure 3.27 HPLC profile of ODN Strand-17 (crude) 
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Figure 3.28 HPLC profile of ODN Strand-17 (pure) 
 
 
Figure 3.29 MALDI-Tof spectrum ODN Strand-17 
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4 Cross-linking Experiments 
4.1 Introduction 
The synthesis of modified and unmodified oligonucleotide has been discussed in 
the previous chapter. The series of cross-linking experiments have been 
performed by mixing a modified ODN strand and its complementary ODN strand 
in MES buffer. These hybrid mixtures were monitored over a length of time by 
HPLC and mass of different fractions collected from HPLC were analyzed by 
MALDI-Tof. The cross-linking was found to be less effective. However, the study 
established the foundation for future research through the development of detailed 
protocols for cross-linking experiments.  
4.2 Design of cross-linking studies 
Cross-linking experiments needed to be designed carefully to observe exact 
changes occurred during the hybridization. The goals of these experiments were 
set as follows; 
4.2.1 The goals 
The synthesis of potential ODN cross-linking agents (modified ODN Strands 1-16) 
was already accomplished. The formation of covalent cross-linking between 
modified ODN strand and an unmodified complementary ODN strand was the 
basis for the development of antisense drug. Therefore, the goals of cross-linking 
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experiments were set to a) to hybridize modified ODN strand with an unmodified 
complementary strand, and b) to detect the potential covalent cross-linking 
between them in real-time. Experiments were carefully designed accomplish these 
to two goals. 
4.2.2 Experimental design 
4.2.2.1 Design of complementary ODN strands 
 
Scheme 4.1 Design of expected cross-linking 
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Unmodified complementary ODN strands were designed by considering their 
potential interactions with corresponding modified ODNs. Nucleobases with exo-
amine groups can react with electrophiles better than the ones without it.[1-7] 
Therefore, complementary ODNs were designed to have either adenine or guanine 
against the modified nucleobase on modified ODN. The potential interactions 
during hybridization are shown in the Scheme 4.1. It is expected that modified ODN 
76 with ester group could interact with an adenine complementary to it on an ODN 
77 to give a cross-linked product 78. Similarly, when guanine on an unmodified 
ODN 79 is complementary to the ester group on an ODN 76, the cross-linked 
product 80 could be the result. Based on these assumptions complementary ODN 
strands for modified ODN Strand 1, 3, 7, 12 and 15 were designed. 
4.2.2.2 Hybridization conditions 
Several hybridization conditions for ODN cross-linking experiments were studied 
carefully.[7-18] Based on these studies we had finalized the following conditions for 
cross-linking experiments. 
The MES buffer (0.1M NaCl, 50 mM MES, pH 5.00) was used as a buffer for 
hybridization experiments. While there are several other buffers mentioned in the 
literature, this is one of the best buffers for fast Interstrand ODN cross-linking.[4, 6, 
16] We decided to move with it keeping all other options open for the future studies. 
The sample amount for OD studies was 2.5 mL and concentration of modified 
ODNs was already available. Based on this concentration quantities of modified 
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ODNs were calculated. We decided to use excess amount of an unmodified 
complementary ODN in each case. The reason for using excess amount of 
complementary ODN was to ensure 100% cross-linking of modified ODN strand 
with it. 
Physiological temperature i.e. 37 °C was the obvious choice for hybridization 
experiments. 
4.2.2.3 Real-time analysis of hybrid mixtures 
The RP-HPLC and MALDI-Tof mass analysis were the best analytical techniques 
to analyze hybrid mixtures. Only a little portion of hybrid mixture needed for RP-
HPLC and even a trace amount of this portion was enough for MALDI-Tof analysis. 
It was possible to study this very little sample over several weeks with these two 
techniques. 
4.3 Results and discussion 
In all five hybridizations were studied under the same conditions mentioned in 
experimental design. One modified ODN strand for each of monomer 1-5 were 
selected. All hybridizations were monitored by RP-HPLC and mass spectra of 
separated fractions were acquired using MALDI-Tof. 
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4.3.1 Hybrid Mixture-1 
 
Scheme 4.2 Expected cross-linking for Hybrid Mixture-1 
The modified ODN Strand-1 was put for hybridization with its complementary ODN 
strand (Hybrid Mixture-1). Cross-linked product-1 was expected to be the result of 
 92   
this interaction (Scheme 4.2). For this hybridization adenine was incorporated on 
the complementary strand facing against a modified nucleobase. 
 
Figure 4.1 HPLC profiles for Hybrid Mixture-1 
The Hybrid Mixture-1 was analyzed by RP-HPLC over the time range of 2h, 12h, 
72h and finally 7 days (Figure 4.1). All RP-HPLC profiles were almost identical with 
two peaks in each one of them. MALDI-Tof mass analysis for two RP-HPLC 
separated peaks was performed. Mass corresponding to RP-HPLC Peak-1 
confirmed the mass for unmodified complementary ODN strand while a mass for 
Peak-2 was found to be for the modified Strand-1 (Figure 4.2). Results found 
indicated that the covalent cross-linking using this modified monomer was not 
achieved, at least for the hybridization conditions used. It was also evident from 
the studies that the modified ODN was stable under the conditions for study without 
any traces of possible hydrolysis product. This stability was perhaps another 
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reason for no cross-linking in this case. Then we moved on to more sensitive ODN 
containing modified monomer 2. 
 
Figure 4.2 Maldi mass analysis of Hybrid Mixture-1 
4.3.2 Hybrid Mixture-2 
Hybrid Mixture-2 was prepared using modified ODN Strand-3 and its 
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complementary strand. The covalent cross-linking product-2 (Scheme 4.3) was 
expected out of this interaction. The Hybrid Mixture-2 was analyzed by RP-HPLC 
over the same time range of 2h, 12h, 72h and finally 7 days (Figure 4.3). For this 
mixture we got only two peaks over the period. Through mass analysis RP-HPLC 
Peak-1 was found to be modified ODN Strand-3 while Peak-2 was confirmed to 
be unmodified complementary ODN strand (Figure 4.4). The results we got for this 
hybridization were not satisfactory either. The reactivity might be the reason again 
just like the first hybridization. 
 
Figure 4.3 HPLC profiles for Hybrid Mixture-2 
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Figure 4.4 Maldi mass analysis of Hybrid Mixture-2 
4.3.3 Hybrid Mixture-3 
The Hybrid Mixture-3 was constituted modified ODN Strand-7 and its 
complementary ODN strand. It was expected to give cross-linked product-3 
(Scheme 4.4) Three RP-HPLC analyses were conducted; first immediately after 
mixing two ODN strands, second after 2h of mixing them and the final one after 
24h (Figure 4.5). The RP-HPLC profile of a mixture immediately after mixing two 
strands together shown two peaks. The rightmost peak on RP-HPLC profiles of 
the mixture labeled as Peak-3 was found to be modified ODN Strand-7 and the 
one labeled as Peak-2 was found to be a complementary ODN strand. 
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Scheme 4.4 Expected cross-linking for Hybrid Mixture-3 
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Figure 4.5 HPLC profiles for Hybrid Mixture-3 
The RP-HPLC profile after 2 hours had shown 3 peaks and we were excited to see 
an additional peak. Unfortunately, the mass analysis of a new peak (Peak-1) was 
found to be a mass for the hydrolyzed product of the modified ODN Strand-7 
(Figure 4.5). Another RP-HPLC analysis was conducted after 24 hours. This time 
the HPLC profile showed only two peaks. The retention time for peak-1 was 
matching with the hydrolyzed product seen previously. Without relying too much 
on HPLC we did MALDI-Tof analysis (Figure 4.6) of the both fractions collected. 
Our guess was found correct that the modified ODN Strand-7 was completely 
hydrolyzed and mass for HPLC peak-1 was found corresponding to the hydrolyzed 
product only. The other peak was unmodified complementary ODN strand. This 
hybridization also found not working under these conditions. The next monomer 
i.e. monomer 4 was expected to be more sensitive than the monomer 3 and we 
were kind of sure about its hydrolysis as well. 
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Figure 4.6 Maldi mass analysis of Hybrid Mixture-3 
4.3.4 Hybrid Mixture-4 
As expected results like Hybrid Mixture-3 were obtained for Hybrid Mixture-4. ODN 
Strand-12 with its unmodified complementary strand were the components of this 
hybrid mixture (Scheme 4.5).  
 100   
 
Scheme 4.5 Expected cross-linking for Hybrid Mixture-4 
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Figure 4.7 Maldi mass analysis of Hybrid Mixture-4 
Two RP-HPLC analysis was conducted; one 2 hours after mixing two strands and 
other after 24h (Figure 4.8). The RP-HPLC profile of a mixture after 2 hours of 
mixing two strands showed three peaks. Peak-1 for hydrolyzed product, Peak-2 
for modified ODN Stand-12 and Peak-3 for unmodified ODN strand.  After 24 
hours modified ODN Strand-12 was completely hydrolyzed and only two peaks on 
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RP-HPLC profile could be seen (Figure 4.8). Mass for each one of them was 
confirmed by MALDI-Tof mass analysis (Figure 4.7). 
 
Figure 4.8 HPLC profiles for Hybrid Mixture-4 
4.3.5 Hybrid Mixture-5 
The Hybrid Mixture-5 was composed of modified ODN Strand-15 and the ODN 
strand complementary to it and was expected to give cross-linked product-5 
(Scheme 4.6). The RP-HPLC analyses (Figure 4.9) for 2 hours showed two distinct 
peaks. Peak-1 was found to be the modified ODN Strand-15 and Peak-2 was 
unmodified complementary ODN strand. After 48 hours RP-HPLC was conducted 
to see the changes but this time got very complex profile. The mass analysis 
(Figure 4.10) for all fractions collected confirmed presence of modified and 
unmodified strands in their original forms. 
 
 103   
 
Scheme 4.6 Expected cross-linking for Hybrid Mixture-5 
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Figure 4.9 HPLC profiles for Hybrid Mixture-5 
 
Figure 4.10 Maldi mass analysis of Hybrid Mixture-5 
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The experiments conducted for cross-linking studies were not satisfactory but the 
synthesis of ODNs with very sensitive groups was first of its kind of achievement. 
Therefore, we decided to publish a synthesis part of the study. Accordingly it was 
published in one of the reputed journal in the field of chemistry.[19] 
4.4 Experimental section 
4.4.1 General experimental 
The RP HPLC was performed on a JASCO LC-2000Plus System: pump, PU-
2089Plus Quaternary Gradient; detector UV-2075Plus. For RP-HPLC a C-18 
reverse phase analytical column (5μm diameter, 100 Å, 250 × 3.20 mm) was used. 
RP-HPLC mobile phase: Solvent A: 0.1 M triethylammonium acetate, 5% aqueous 
acetonitrile. Solvent B: 90% aqueous acetonitrile. RP-HPLC profiles were 
generated by detection of absorbance of ODN at 260 nm using the linear gradient 
solvent system: solvent B (0%-45%) in Solvent A over 60 min followed by Solvent 
B (45%-100%) in Solvent A over 20 min at a flow rate of 1.0 mL/min. The RP-
HPLC separated peaks were analyzed by Bruker Microflex LRF MALDI-Tof to 
confirm their mass. 
4.4.2 Preparation of Hybrid Mixtures 1-5 
MES buffer (0.1 M NaCl, pH=5.01, 50 mM) was prepared according the standard 
procedure.[4, 6] The solutions 50 µL of each of modified ODNs and unmodified 
complementary ODNs were prepared in the freshly prepared buffer in Eppendorf 
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tubes. Annealing of ODN solutions were carried out at 90 °C for 5 minutes. 
Annealing of ODN solutions for Strand-7, 12 and 15 was avoided to check the 
potential hydrolysis of very sensitive ester groups on them. Appropriate ODNs 
were mixed together to get Hybrid Mixtures 1-5. 
4.4.3 RP-HPLC and MALDI-Tof analysis 
The RP-HPLC was conducted using the conditions mentioned in general 
experimental. The peaks shown on RP-HPLC profiles were collected cautiously to 
avoid any mixing in 100 µL fractions. The collected RP-HPLC fractions were used 
as samples for MALDI-Tof analysis without further processing. Further processing 
might have destroyed the products or at least could hydrolyzed the sensitive ester 
groups. MALDI-Tof mass determination was conducted by following the same 
procedure mentioned in Chapter 3. Results obtained were compared with the 
theoretical values. 
4.5 Conclusion and future work 
The ODN cross-linking agents we designed and synthesized did not cross-link as 
we expected. Some of them remained unreacted over the period of several days 
while the ones with sensitive esters were completely hydrolyzed within 24 hours 
without cross-linking. However, we had successfully incorporated sensitive groups 
into oligonucleotide which are not possible to install by standard oligonucleotide 
synthesis. The procedures and protocols developed for the synthesis of monomers 
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and ODNs, cross-linking experiments, real-time monitoring of hybrid mixtures, 
analysis by HPLC and MALDI-Tof is the foundation for our future studies.  
In the future we intend to design and synthesize more potential cross-linking 
agents and search will continue till we get the positive results. The search for an 
ideal oligonucleotide cross-linking agent has become easy because of this study. 
There is a need of several trial experiments to accomplish the desired cross-linking 
agent.  
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5 Appendices 
A.1 NMR data for Chapter 2 
A.1.1 1H NMR of Compound 38 in CDCl3, 400 MHz  
 
 110   
A.1.2 13C NMR of Compound 38 in CDCl3, 100 MHz  
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A.1.3 1H NMR of Compound 42a in CDCl3, 400 MHz 
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A.1.4 13C NMR of Compound 42a in CDCl3, 100 MHz  
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A.1.5 1H NMR of Compound 43a in CDCl3, 400 MHz  
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A.1.6 13C NMR of Compound 43a in CDCl3, 100 MHz  
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A.1.7 1H NMR of Compound 1 in CDCl3, 400 MHz  
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A.1.8 13C NMR of Compound 1 in CDCl3, 100 MHz  
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A.1.9 31P NMR of Compound 1 in CDCl3, 162 MHz  
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A.1.10 1H NMR of Compound 39 in CDCl3, 400 MHz  
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A.1.11 13C NMR of Compound 39 in CDCl3, 100 MHz  
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A.1.12 1H NMR of Compound 41a in CDCl3, 400 MHz 
 
 121   
A.1.13 13C NMR of Compound 41a in CDCl3, 100 MHz  
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A.1.14 1H NMR of Compound 42b in CDCl3, 400 MHz  
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A.1.15 13C NMR of Compound 42b in CDCl3, 100 MHz  
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A.1.16 1H NMR of Compound 43b in CDCl3, 400 MHz  
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A.1.17 13C NMR of Compound 43b in CDCl3, 100 MHz  
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A.1.18 1H NMR of Compound 2 in CDCl3, 400 MHz 
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A.1.19 13C NMR of Compound 2 in CDCl3, 100 MHz 
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A.1.20 31P NMR of Compound 2 in CDCl3, 162 MHz 
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A.1.21 1H NMR of Compound 41b in CDCl3, 400 MHz 
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A.1.22 13C NMR of Compound 41b in CDCl3, 100 MHz 
 
 131   
A.1.23 1H NMR of Compound 42c in CDCl3, 400 MHz 
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A.1.24 13C NMR of Compound 42c in CDCl3, 100 MHz 
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A.1.25 1H NMR of Compound 43c in CDCl3, 400 MHz 
 
 134   
A.1.26 13C NMR of Compound 43c in CDCl3, 100 MHz 
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A.1.27 1H NMR of Compound 3 in CDCl3, 400 MHz 
 
 136   
A.1.28 13C NMR of Compound 3 in CDCl3, 100 MHz 
 
 137   
A.1.29 31P NMR of Compound 3 in CDCl3, 162 MHz 
 
 138   
A.1.30 1H NMR of Compound 41c in CDCl3, 400 MHz 
 
 139   
A.1.31 13C NMR of Compound 41c in CDCl3, 100 MHz 
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A.1.32 1H NMR of Compound 42d in CDCl3, 400 MHz 
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A.1.33 13C NMR of Compound 42d in CDCl3, 100 MHz 
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A.1.34 1H NMR of Compound 43d in CDCl3, 400 MHz 
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A.1.35 13C NMR of Compound 43d in CDCl3, 100 MHz 
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A.1.36 1H NMR of Compound 4 in CDCl3, 400 MHz 
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A.1.37 13C NMR of Compound 4 in CDCl3, 100 MHz 
 
 146   
A.1.38 31P NMR of Compound 4 in CDCl3, 162 MHz 
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A.1.39 1H NMR of Compound 41d in CDCl3, 400 MHz 
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A.1.40 13C NMR of Compound 41d in CDCl3, 100 MHz 
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A.1.41 1H NMR of Compound 42e in CDCl3, 400 MHz 
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A.1.42 13C NMR of Compound 42e in CDCl3, 100 MHz 
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A.1.43 1H NMR of Compound 43e in CDCl3, 400 MHz 
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A.1.44 13C NMR of Compound 43e in CDCl3, 100 MHz 
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A.1.45 1H NMR of Compound 5 in CDCl3, 400 MHz 
 
 154   
A.1.46 13C NMR of Compound 5 in CDCl3, 100 MHz 
 
 155   
A.1.47 31P NMR of Compound 5 in CDCl3, 162 MHz 
  
 156   
A.1.48 1H NMR of Compound 59 in DMSO, 400 MHz 
  
 157   
A.1.49 13C NMR of Compound 59 in DMSO, 100 MHz 
  
 158   
A.1.50 1H NMR of Compound 60 in CDCl3, 400 MHz 
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A.1.51 13C NMR of Compound 60 in CDCl3, 100 MHz 
  
 160   
A.1.52 1H NMR of Compound 6 in CDCl3, 400 MHz 
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A.1.53 13C NMR of Compound 6 in CDCl3, 100 MHz 
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A.1.54 31P NMR of Compound 6 in CDCl3, 162 MHz 
 
 163   
A.2 HPLC profiles of oligonudeoxynucleotides for chapter 3 
A.2.1 Crude oligodeoxynucleotide Strand-1 
 
 
A.2.2 Pure oligodeoxynucleotide Strand-1 
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A.2.3 Crude oligodeoxynucleotide Strand-2 
 
 
A.2.4 Pure oligodeoxynucleotide Strand-2 
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A.2.5 Crude oligodeoxynucleotide Strand-3 
 
 
A.2.6 Pure oligodeoxynucleotide Strand-3 
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A.2.7 Crude oligodeoxynucleotide Strand-4 
 
 
A.2.8 Pure oligodeoxynucleotide Strand-4 
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A.2.9 Crude oligodeoxynucleotide Strand-5 
 
 
A.2.10 Pure oligodeoxynucleotide Strand-5 
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A.2.11 Crude oligodeoxynucleotide Strand-6 
 
 
A.2.12 Pure oligodeoxynucleotide Strand-6 
 
 
 
[min.]0 10 20 30 40 50
A
b
s 
(2
6
0
n
m
)
0
10
20
30
40
50
[min.]0 10 20 30 40 50
A
b
s 
(2
6
0
n
m
)
0
10
20
30
40
 169   
A.2.13 Crude oligodeoxynucleotide Strand-7 
 
 
A.2.14 Pure oligodeoxynucleotide Strand-7 
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A.2.15 Cure oligodeoxynucleotide Strand-8 
 
 
A.2.16 Pure oligodeoxynucleotide Strand-8 
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A.2.17 Crude oligodeoxynucleotide Strand-9 
 
 
 
A.2.18 Pure oligodeoxynucleotide Strand-9 
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A.2.19 Crude oligodeoxynucleotide Strand-10 
 
 
A.2.20 Pure oligodeoxynucleotide Strand-10 
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A.2.21 Crude oligodeoxynucleotide Strand-11 
 
 
 
A.2.22 Pure oligodeoxynucleotide Strand-11 
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A.2.23 Crude oligodeoxynucleotide Strand-12 
 
 
 
A.2.24 Pure oligodeoxynucleotide Strand-12 
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A.2.25 Crude oligodeoxynucleotide Strand-13 
 
 
A.2.26 Pure oligodeoxynucleotide Strand-13 
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A.2.27 Crude oligodeoxynucleotide Strand-14 
 
 
 
A.2.28 Pure oligodeoxynucleotide Strand-14 
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A.2.29 Crude oligodeoxynucleotide Strand-15 
 
 
A.2.30 Pure oligodeoxynucleotide Strand-15 
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A.2.31 Crude oligodeoxynucleotide Strand-16 
 
 
A.2.32 Pure oligodeoxynucleotide Strand-16 
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A.2.33 Crude oligodeoxynucleotide Strand-17 
 
 
A.2.34 Pure oligodeoxynucleotide Strand-17 
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A.2.35 Crude oligodeoxynucleotide Strand-18 
 
 
A.2.36 Pure oligodeoxynucleotide Strand-18 
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A.3 MALDI-Tof spectra of oligodeoxynucleotides chapter-3 
A.3.1 Mass spectrum for ODN Strand-1 
 
 
A.3.2 Mass spectrum for ODN Strand-2 
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A.3.3 Mass spectrum for ODN Strand-3 
 
 
A.3.4 Mass spectrum for ODN Strand-4 
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A.3.5 Mass spectrum for ODN Strand-5 
 
 
A.3.6 Mass spectrum for ODN Strand-6 
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A.3.7 Mass spectrum for ODN Strand-7 
 
 
A.3.8 Mass spectrum for ODN Strand-8 
 
 
 
6195.003
3095.812
2064.269
0
1000
2000
3000I
nt
en
s.
 [
a.
u.
]
2000 3000 4000 5000 6000 7000 8000 9000
m/z
6266.896
3132.493
0
50
100
150
200
250
300
In
te
ns
. [
a.
u.
]
2000 3000 4000 5000 6000 7000 8000 9000
m/z
 185   
A.3.9 Mass spectrum for ODN Strand-9 
 
 
A.3.10 Mass spectrum for ODN Strand-10 
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A.3.11 Mass spectrum for ODN Strand-11 
 
 
A.3.12 Mass spectrum for ODN Strand-12 
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A.3.13 Mass spectrum for ODN Strand-13 
 
 
A.3.14 Mass spectrum for ODN Strand-14 
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A.3.15 Mass spectrum for ODN Strand-15 
 
 
A.3.16 Mass spectrum for ODN Strand-16 
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A.3.17 Mass spectrum for ODN Strand-17 
 
 
A.3.18 Mass spectrum for ODN Strand-18 
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A.4 UV-Visible spectra of oligonucleotides chapter 3 
A.4.1 UV-Visible spectrum for ODN Strand-1 
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A.4.2 UV-Visible spectrum for ODN Strand-2 
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A.4.3 UV-Visible spectrum for ODN Strand-3 
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A.4.4 UV-Visible spectrum for ODN Strand-4 
240 260 280 300 320 340 360 380 400
0.00
0.05
0.10
0.15
0.20
0.25
0.2108
A
b
so
rb
an
ce
Wavelength (nm)  
192 
A.4.5 UV-Visible spectrum for ODN Strand-5 
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A.4.6 UV-Visible spectrum for ODN Strand-6 
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A.4.7 UV-Visible spectrum for ODN Strand-7 
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A.4.8 UV-Visible spectrum for ODN Strand-8 
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A.4.9 UV-Visible spectrum for ODN Strand-9 
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A.4.10 UV-Visible spectrum for ODN Strand-10 
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A.4.11 UV-Visible spectrum for ODN Strand-11 
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A.4.12 UV-Visible spectrum for ODN Strand-12 
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A.4.13 UV-Visible spectrum for ODN Strand-13 
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A.4.14 UV-Visible spectrum for ODN Strand-14 
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A.4.15 UV-Visible spectrum for ODN Strand-15
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A.4.16 UV-Visible spectrum for ODN Strand-16 
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A.4.17 UV-Visible spectrum for ODN Strand-17 
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A.4.18 UV-Visible spectrum for ODN Strand-18 
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A.5 Permission from a publisher 
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